Bipolar Disorder

🏷

Classifications

Harrison's Part

◆

Subtypes

3

Bipolar I Disorder

Characterized by manic episodes, with or without depressive episodes.

Show evidence (1 reference)

PMID:31043756 SUPPORT Human Clinical

"Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis"

Large GWAS shows bipolar I disorder is genetically distinguished from bipolar II by its strong correlation with schizophrenia and psychosis.

Bipolar II Disorder

Characterized by hypomanic and depressive episodes, no full mania.

Show evidence (1 reference)

PMID:31043756 SUPPORT Human Clinical

"bipolar II disorder is more strongly correlated with major depressive disorder"

GWAS genetic-correlation analysis distinguishes bipolar II disorder from bipolar I by its stronger correlation with major depressive disorder.

Cyclothymic Disorder

Chronic fluctuating mood with hypomanic and depressive symptoms.

◈

Mechanistic Hypotheses

1

Canonical Polygenic / Synaptic / Circadian Dysregulation Model

canonical_polygenic_synaptic_circadian_dysregulation_model CANONICAL

Evidence balance 9 support 1 refute 1 no evidence

Bipolar disorder is a highly heritable polygenic mood disorder in which common variants in CACNA1C, ANK3, ODZ4, and other ion-channel and synaptic genes combine with circadian/clock gene variants (CLOCK, BMAL1, NR1D1) to produce episodic mood instability. Mitochondrial dysfunction, calcium-signaling dysregulation, and altered neuroplasticity in fronto-limbic circuits (anterior cingulate, amygdala, ventral striatum) drive cycling between depressive and manic states. Lithium's mood-stabilizing efficacy (targeting GSK-3β / inositol monophosphatase / circadian amplitude), valproate's modulation of histone deacetylases, and the recurrent involvement of the dopaminergic reward system during manic episodes corroborate the polygenic-synaptic-circadian framework as the canonical model.

Retained as CANONICAL with six explicit qualifications, independently re-verified against the cited primary sources rather than the 2026 openscientist hypothesis-search report's framing (kb/hypotheses/Bipolar_Disorder/canonical_polygenic_synaptic_circadian_dysregulation_model), which finds PARTIALLY SUPPORTED. Each major pillar — common ion-channel / synaptic gene variants (CACNA1C, ANK3, ODZ4), circadian/clock variants, mitochondrial dysfunction, calcium signaling, and fronto-limbic neuroplasticity — has substantial GWAS, iPSC, animal-model, and pharmacological support, with lithium and valproate efficacy and dopaminergic mania consistent with the model. The 2025 multi-ancestry PGC4 GWAS (298 genome-wide-significant loci across 158,036 cases and 2.8 million controls, PMID:39843750) is the current largest genetic-architecture study of BD and supersedes the smaller PGC3 scan the report's genetics framing was based on. Six qualifications, each rescoped to what its cited study actually shows: (1) postmortem cortical transcriptome data (PMID:33442739) show a less-pronounced, psychosis-concentrated similarity between schizophrenia and BD gene-expression alterations — the study never tested the canonical calcium/circadian/synaptic model and did not restrict its BD sample to BD-I, so it qualifies rather than establishes that the model "best explains psychotic BD-I"; (2) the calcium-channel-blocker translational picture is a small, unresolved lead rather than a demonstrated dihydropyridine-vs-verapamil subclass effect — the decisive verapamil-to-dihydropyridine (nimodipine, then isradipine) response switch involved only two bipolar patients embedded in a 30-person mixed unipolar/bipolar refractory-affective-illness cohort (PMID:9790159), and a broader review of calcium-channel antagonist trials in BD found only limited support for efficacy (PMID:11252650); (3) lithium response pharmacogenomics implicates PI3K-Akt / focal-adhesion pathways rather than direct GSK-3β (partially reconcilable via the PI3K→Akt→GSK-3β cascade); (4) TIMELESS and RORA are circadian-gene leads from a single 2014 candidate-gene association study (353 SNPs across 21 circadian genes, meta-analysed across two internal BD cohorts, PMID:24716566), not an update established across the modern GWAS literature, so they supplement rather than displace CLOCK/BMAL1 as canonical circadian candidates; (5) the claim that BD-risk-gene-attributed structural abnormalities are shared across the psychosis spectrum conflates two weaker, separate findings — a candidate-SNP imaging study of CACNA1C/ANK3/ODZ4/SYNE1 found no risk-variant-structural association surviving multiple-testing correction (PMID:23820096), so there is no confirmed gene-attributed structural finding to generalize from, and a separate ENIGMA mega-/meta-analysis found shared cortical/subcortical abnormalities across BD, schizophrenia, major depressive disorder, and OCD generally (PMID:32646651) — a transdiagnostic pattern, not one specific to a psychosis spectrum or tied to risk-gene status; (6) critical experiments remain largely unperformed — no GSK-3β-selective inhibitor trial and no chronotherapy prevention trial from euthymia exist as of 2026, and while a modern dihydropyridine CCB trial was registered (adjunctive isradipine for bipolar depression, NCT01784666), it was terminated early for lack of enrollment (2 participants), so an adequately powered modern DHP-CCB trial remains a real gap rather than one that was never attempted.

Deep research

OpenScientist citations 49 citations 2026-05-24T15:55:47.427164

Show evidence (11 references)

PMID:21057379 SUPPORT Human Clinical

"The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."

Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.

PMID:33442739 SUPPORT Human Clinical

"correlation analyses showed that BP subjects had similar, although less pronounced, gene expression alterations"

Postmortem cortical transcriptome comparison finds BD subjects share schizophrenia-like gene-expression alterations, but only less pronounced ones concentrated among BD subjects with psychosis. The case-control study did not test the canonical calcium/circadian/synaptic model directly and did not restrict its BD sample to BD-I, so it qualifies rather than establishes that the model "best explains psychotic BD-I."

PMID:9790159 SUPPORT Human Clinical

"two BP patients failed to maintain improvement but responded again to nimodipine and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine"

The decisive verapamil-to-dihydropyridine response switch cited for the pharmacological-subclass hypothesis involved only two bipolar patients within a 30-person mixed-diagnosis refractory-affective-illness cohort — a small case-series lead, not a demonstrated subclass effect.

+ 8 more references

?

Discussions and Knowledge Gaps

4

What determines the switch between manic and depressive states in bipolar disorder, and in what temporal order do the components of the canonical model change around a switch - does calcium dysregulation precede circadian disruption, the reverse, or do both follow an upstream trigger not yet in the model?

KNOWLEDGE GAP OPEN gap_bipolar_episodic_switching_trigger

Attached to

mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model pathophysiology#Intracellular Calcium Dysregulation pathophysiology#Circadian Rhythm Disruption

Episodic cycling is the defining clinical feature of bipolar disorder and is the part of the canonical model with the weakest evidential support. Every pillar curated in this entry is a vulnerability or trait finding rather than a transition mechanism, and this shows up consistently in the primary sources rather than only in the abstract. The replicated peripheral-cell calcium abnormality showed little correlation with mood-rating severity in the series that established it (PMID:10418700), so the most reproducible cellular finding in the field is not obviously state-coupled. The patient-derived neuron work characterizes hyperexcitability as an early endophenotype in young neurons (PMID:26524527), not as a state marker. The strongest causal circadian manipulation available produces a single mixed state rather than alternation between separable poles (PMID:20591414). The phasic mitochondrial account that does address state (PMID:28093238) is explicitly a proposed explanatory model synthesizing cross-sectional comparisons, not a study of transition dynamics: comparing manic to euthymic subjects establishes that states differ, which is a different claim from establishing what moves a patient between them. This gap is the substantive content of the PARTIALLY_SUPPORTED verdict returned by the 2026 OpenScientist assessment of this hypothesis - the framework organizes vulnerability well and does not currently explain episodicity - and it is why the entry retains CANONICAL status for the vulnerability model without asserting a switching mechanism.

Proposed experiments

Densely sampled longitudinal multi-omics through a mood switch

longitudinal within-subject observational study

exp_bipolar_peri_switch_longitudinal_multiomics

Follow rapid-cycling bipolar patients through spontaneous mood transitions with dense temporal sampling - weekly peripheral blood for intracellular calcium, transcriptomics, cytokines and cortisol, continuous actigraphy and sleep timing for circadian phase, and periodic imaging - so that the order in which calcium, circadian and inflammatory measures change relative to clinical switch can be established within individuals. Within-subject design is essential: cross-sectional comparison of manic and euthymic groups cannot recover temporal ordering.

Decision criterion

The model gains a switching mechanism only if a measured change in a curated node reliably precedes clinical switch within individuals. Change that follows the switch, or that does not replicate across patients, leaves the gap open regardless of effect size.

Would support

pathophysiology#Intracellular Calcium Dysregulation pathophysiology#Circadian Rhythm Disruption mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model

Would refute

mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model

Supporting outcome

Calcium or circadian measures change reproducibly in a consistent direction and in a consistent order in the days preceding clinical switch, across multiple patients and multiple switches, which would promote the corresponding node from a trait association to a step in the switching mechanism.
Circadian phase shift consistently precedes the calcium change, which would order the two pillars and identify circadian destabilization as the proximal trigger rather than a parallel correlate.

Refuting outcome

Calcium and circadian measures remain flat across switches, or change only after clinical state has already changed, which would establish them as trait vulnerability markers and consequences respectively and force the switching trigger to be sought outside the components this model names.

Show evidence (2 references)

PMID:10418700 SUPPORT Human Clinical

"We also found little correlation between calcium measures and the severity of mood rating."

The null result that opens this gap. The same study that established the elevated-calcium finding found it did not track mood severity, so the field's most replicated cellular abnormality is not demonstrably state-coupled.

PMID:28093238 SUPPORT Other

"there is accumulating evidence indicating increased mitochondrial respiration and ATP production in bipolar mania which contrasts with decreased mitochondrial function in patients in the euthymic or depressive phase of the illness"

States the phasic proposal that is currently the field's best answer to the switching question, and shows what it rests on: cross-sectional contrasts between mood states. Establishing that states differ is not the same as establishing what causes transition between them, which is why the gap remains open.

Do the calcium-channel susceptibility loci shared between bipolar disorder and cardiovascular disease (the established CACNA1C locus plus the pleiotropic genes TPCN1, CACNA2D2, CACNA1D, and ATP2B1) reflect a single causal calcium-signaling axis acting in both brain and cardiovascular tissue, and what is the direction of causation - does psychiatric-risk calcium-channel genotype drive cardiac electrophysiological change (e.g., QTc prolongation), or the converse?

KNOWLEDGE GAP OPEN gap_bipolar_calcium_channel_psychiatric_cardiovascular_pleiotropy

Attached to

genetic#CACNA1C

A genome-wide pairwise pleiotropy study in East Asians (Zhu et al., 2026; PMID:42436150) found shared genetic architecture across psychiatric and cardiovascular disease pairs converging on voltage-dependent calcium-channel activity, with novel pleiotropic genes (TPCN1, CACNA2D2, CACNA1D, ATP2B1) enriched in the calcium-signaling pathway alongside the established bipolar/schizophrenia locus CACNA1C. A calcium-pathway polygenic risk score was associated with prolonged QTc, and drug-target analysis implicated calcium-channel blockers and peripheral vasodilators in elevated schizophrenia risk while diuretics reduced risk across schizophrenia, bipolar disorder, and major depressive disorder. The unresolved gaps are (1) whether the same calcium-channel variants are the primary driver in brain versus a secondary consequence in cardiovascular tissue (tissue-specific direction of effect), (2) the causal direction of the calcium-genotype to QTc association, and (3) the mechanistic basis for the apparent antagonistic pleiotropy in treatment response - why L-type calcium-channel modulation may be relevant to mood episodes yet calcium-channel blockade associates with increased psychiatric risk at the population-genetic level. Resolving this bears directly on the safety of calcium-channel blockers in patients with concurrent bipolar disorder and cardiovascular disease. This is a cross-disease gap shared with the Schizophrenia, Major Depressive Disorder, and Coronary Artery Disease entries (dismech issue #6382).

Proposed experiments

Tissue-stratified Mendelian randomization of the calcium axis

Mendelian randomization study

exp_bipolar_calcium_pleiotropy_tissue_mr

Use brain- and cardiovascular-tissue eQTLs to instrument the pleiotropic calcium-channel genes (CACNA1C, CACNA1D, CACNA2D2, ATP2B1, TPCN1) in bidirectional Mendelian randomization against bipolar disorder, schizophrenia, QTc interval, and coronary artery disease, across independent and cross-ancestry cohorts.

Decision criterion

A shared causal calcium-signaling axis would be supported if the same tissue-specific calcium-channel instruments showed concordant, directional effects on both psychiatric and cardiovascular endpoints; discordant or tissue-limited effects would instead argue for parallel, tissue-restricted mechanisms.

Show evidence (2 references)

PMID:42436150 SUPPORT Computational

"Among the novel pleiotropic genes, TPCN1, CACNA2D2, CACNA1D, and ATP2B1 are involved in voltage-dependent calcium channel activity, regulation of calcium influx, enriched in calcium-related pathway."

Genome-wide pairwise pleiotropy analysis identifies shared calcium-channel genes across psychiatric and cardiovascular disease, motivating the shared-axis question.

PMID:42436150 SUPPORT Computational

"Our findings implicated that calcium-channel blockers and peripheral vasodilators elevated SCZ risk, diuretics reduced the risks of SCZ, BIP, and MDD."

Drug-target analysis underpinning the antagonistic-pleiotropy treatment-response gap for calcium-channel modulation.

Does the SETD1A p.Pro596Leu association with bipolar disorder replicate outside the Lancaster Old Order Amish founder population, and is SETD1A a bipolar-disorder risk gene in its own right or only a schizophrenia and neurodevelopmental-disorder risk gene whose carriers are sometimes given a mood-disorder diagnosis?

KNOWLEDGE GAP OPEN gap_bipolar_setd1a_p596l_replication

Attached to

genetic#SETD1A

SETD1A is one of the most robustly established schizophrenia risk genes (genome-wide significant for rare loss-of-function variants in Singh et al. 2016, and one of ten exome-wide-significant genes in SCHEMA). Its relationship to bipolar disorder is not established. The only direct evidence is a founder-population missense allele associated with a 1.8-fold relative risk at P = 0.027 - nominal, uncorrected, single-population, and reported in a non-peer-reviewed preprint. Three things make this hard to resolve rather than merely under-powered. (1) The allele is 55-fold enriched in the Old Order Amish and rare elsewhere (0.09% in gnomAD), so direct replication in an unrelated cohort is not feasible for this variant; any replication has to be at gene level, on a different allelic series. (2) The schizophrenia association is driven by loss-of-function alleles, whereas P596L behaves as a hypomorph in patient-derived iPSCs, so a gene-level bipolar test is not testing the same perturbation. (3) Bipolar and schizophrenia diagnoses are not cleanly separable in carriers of large-effect chromatin-regulator variants, so a positive gene-level result would still need to distinguish a bipolar-specific effect from diagnostic assignment within a shared psychosis-spectrum liability. Until then the entry records the allele as a lead, not as a susceptibility locus comparable to CACNA1C or ANK3.

Proposed experiments

Gene-level SETD1A rare-variant burden test in large bipolar cohorts

rare-variant burden association study

exp_bipolar_setd1a_gene_burden

Test rare damaging SETD1A variation for association with bipolar disorder in the largest available bipolar exome or genome collections, stratified by variant class (protein-truncating versus damaging missense), and conditioning on schizoaffective and psychotic-feature status to separate a bipolar-specific signal from shared psychosis-spectrum liability.

Decision criterion

A bipolar-specific role would be supported by exome-wide-significant SETD1A burden in bipolar cases that survives conditioning on psychotic features; a signal that disappears under that conditioning, or that is carried entirely by protein-truncating alleles with no missense contribution, would instead argue that the P596L finding reflects the known schizophrenia and neurodevelopmental association rather than a distinct bipolar mechanism.

Show evidence (2 references)

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT Human Clinical

"was associated with a 1.8-fold relative risk for BD in our sample (P = 0.027; Fig. 1A)."

The nominal, single-population association that motivates the gap.

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT Human Clinical

"associated with bipolar disorder risk and cognitive deficits in specific sub-domains."

The authors' own summary of what the variant is and is not shown to do - a risk association plus selective cognitive deficits, with no claim of an established bipolar-disorder locus.

Which gene at the 3p21.1 locus carries the risk signal shared between bipolar disorder and obsessive-compulsive disorder, and is prefrontal-cortex H3K27ac histone acetylation the regulatory mechanism through which it acts - or is the ITIH3/ITIH4 prioritization an artifact of the long-range linkage disequilibrium that also spans GLT8D1, SFMBT1, NEK4 and NISCH?

KNOWLEDGE GAP OPEN gap_bip_ocd_3p21_1_effector_gene_and_h3k27ac

Attached to

genetic#ITIH3

3p21.1 is genome-wide significant in the largest GWAS of both disorders, and a 2026 cross-trait analysis (conjFDR, SMR, multi-omic colocalization) prioritizes ITIH3/ITIH4 as the shared pleiotropic signal, with SNPs colocalizing with H3K27ac haQTLs in prefrontal cortex. That result is preprint-level, statistical, and directly contradicted in its gene assignment by the only functional dissection of the region published to date: CRISPR-Cas9 editing of rs2535629, which lies inside an ITIH3 intron, changed expression of the distal genes GLT8D1, SFMBT1 and NEK4 rather than of ITIH3, and the authors attributed schizophrenia risk to SFMBT1. So an intronic ITIH3 variant is a bona fide chromatin-regulatory variant at this locus while ITIH3 is not its target - which is precisely the confound a colocalization-only analysis cannot resolve. Resolving this matters because the two candidate effectors imply different biology: ITIH3/ITIH4 are hyaluronan-binding extracellular-matrix cross-linkers (the theme already represented by the bipolar NCAN locus), whereas SFMBT1 is a polycomb-family chromatin regulator of dendritic spine density. The clinical stake is real rather than hypothetical: OCD comorbidity in bipolar disorder is associated with a measurably worse course, so a shared causal mechanism would be a tractable target.

Show evidence (3 references)

PPR:PPR1294131 Preprint · not peer-reviewed SUPPORT Computational

"where multiple SNPs (e.g., rs3774364) colocalized with H3K27ac histone acetylation QTLs in the prefrontal cortex (PP_H4 > 0.5)"

States the preprint's specific mechanistic proposal - prefrontal-cortex H3K27ac histone-acetylation QTL colocalization at the prioritized locus - which is one side of this gap.

PMID:34978167 SUPPORT In Vitro

"Interestingly, differential expression analysis of GLT8D1, SFMBT1, and NEK4 suggested that rs2535629 may confer schizophrenia risk by regulating SFMBT1 expression."

The one functional dissection of a 3p21.1 psychiatric risk variant assigns the effect of an ITIH3-intronic SNP to distal genes, concluding SFMBT1 is the mediator. PARTIAL because the disorder studied was schizophrenia, not bipolar disorder or OCD; it constrains the gene assignment at this locus rather than settling it for these two disorders.

PMID:40855518 SUPPORT Human Clinical

"BD-OCD presents a more severe and complex clinical profile, requiring specialized assessment and integrated treatment approaches."

Peer-reviewed meta-analysis of 22 studies establishing that the bipolar-OCD comorbidity carries a distinct and more severe clinical profile, which is why a shared causal locus is worth resolving.

⚙

Pathophysiology

9

Monoamine Dysregulation

Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.

Dopaminergic Neuron CL:0000700 Serotonergic Neuron CL:0000850 Noradrenergic Neuron CL:0008025

Neurotransmitter Signaling GO:0007268

Show evidence (2 references)

PMID:22363263 SUPPORT

"Activation of the dopamine receptor 2 (D2R) has been shown to stimulate the inactivation of Akt by PP2A (Beaulieu et al., 2005; Beaulieu and Gainetdinov, 2011), therefore providing a mechanism through which GPCR activation can inhibit Akt in response to extracellular signals."

Dopamine D2 receptor signaling regulates the Akt/GSK3 pathway, providing a molecular link between monoaminergic neurotransmission and mood regulation in bipolar disorder.

PMID:22363263 SUPPORT

"This mechanism of D2R signaling appears to play important roles in the regulation of locomotor behavior and sensory motor gating by dopamine (Beaulieu et al., 2004; Emamian et al., 2004). It could also contribute to the therapeutic and/or adverse effects of psychoactive drugs like amphetamines..."

The D2 receptor-mediated regulation of GSK3 activity through beta-arrestin signaling is implicated in behavioral regulation relevant to bipolar disorder and the mechanism of mood stabilizers and antipsychotics.

Intracellular Calcium Dysregulation

Altered intracellular calcium handling is among the oldest and most replicated cellular findings in bipolar disorder: basal and stimulated cytosolic calcium are elevated in patient platelets and lymphocytes, and endoplasmic-reticulum calcium release through the IP3 receptor is enhanced in patient lymphoblasts carrying the low-expressing BCL2 rs956572 AA genotype. This is the cellular counterpart of the calcium-channel genetics curated under CACNA1C. Two scope limits are load-bearing and should not be read past: the replicated measurements are in peripheral blood cells rather than neurons, and they have not been shown to track mood state over time -- the original series found little correlation between calcium measures and mood-rating severity. The node therefore records a trait-associated calcium abnormality, not a demonstrated driver of episode switching (see the attached knowledge gap).

Intracellular Calcium Homeostasis GO:0006874 ⚠ ABNORMAL IP3 Receptor-Mediated ER Calcium Release GO:0051209 ↑ INCREASED

Downstream

Mitochondrial Dysfunction Proposed rather than demonstrated. A published model argues that raised cytosolic calcium in mania drives increased mitochondrial respiration and ATP production, with the euthymic and depressive phases showing the opposite. No study cited here measures calcium and mitochondrial respiration in the same subjects across a mood transition, so the edge is recorded at unknown-intermediate directness.

Show evidence (4 references)

PMID:10418700 SUPPORT Human Clinical

"We observed significantly elevated basal calcium concentrations in bipolar patient platelets and lymphocytes compared to control subjects."

Direct measurement of the elevated basal calcium finding in 30 affective disorder patients versus 14 controls, the replicated peripheral-cell observation this node records.

PMID:10418700 SUPPORT Human Clinical

"our data suggest that storage operated calcium channels may be the source of the elevated intracellular calcium in platelets and lymphocytes of bipolar patients"

Locates the abnormality at store-operated calcium entry rather than at the plasma-membrane voltage-gated channels implicated by the CACNA1C genetics, so the two calcium findings are complementary rather than the same lesion measured twice.

PMID:21167476 SUPPORT In Vitro

"These results demonstrate that, in patients with BPD, abnormal Bcl-2 gene expression in the AA variant contributes to dysfunctional Ca(2+) homeostasis through a specific ER inositol 1,4,5-trisphosphate receptor-dependent mechanism."

Supplies a genotype-to-mechanism account for part of the calcium abnormality: reduced BCL2 expression in rs956572 AA carriers enhances IP3-receptor-dependent ER calcium release. Scope caveat -- 18 patient lymphoblast lines, a peripheral cell model, not neurons.

+ 1 more reference

Neuronal Hyperexcitability

Patient-derived neurons show intrinsic hyperexcitability, offering a cellular endophenotype that sits between the ion-channel genetics and the circuit-level findings. iPSC-derived hippocampal dentate-gyrus-like granule neurons from bipolar patients fire action potentials hyperactively and carry mitochondrial abnormalities relative to control-derived neurons. The finding is also a treatment-response stratifier: lithium reverses the hyperexcitability only in neurons from donors who were themselves clinical lithium responders. Scope limits -- six manic bipolar I donors and four unaffected individuals, one differentiated neuron type, and no demonstration that hyperexcitability causes episode switching rather than marking trait vulnerability.

iPSC-derived hippocampal dentate gyrus-like granule neuron CL:0001033

Action Potential Firing GO:0001508 ↑ INCREASED Regulation of Neuronal Membrane Potential GO:0042391 ⚠ ABNORMAL

Experimental models

Bipolar patient iPSC-derived hippocampal dentate gyrus-like neurons IPSC DERIVED MODEL Neurons from patients fire action potentials more readily than neurons from unaffected individuals. Lithium reverses the difference only in neurons from patients who responded to lithium clinically. This node was curated from this study.

Show evidence (2 references)

PMID:26524527 SUPPORT DIRECT In Vitro

"we have detected mitochondrial abnormalities in young neurons from patients with bipolar disorder by using mitochondrial assays; in addition, using both patch-clamp recording and somatic Ca(2+) imaging, we have observed hyperactive action-potential firing."

The primary measurement behind this node: patch-clamp and calcium imaging in patient-derived dentate-gyrus-like neurons show hyperactive action-potential firing alongside mitochondrial abnormalities, in patient-derived human tissue rather than an animal model.

PMID:26524527 SUPPORT In Vitro

"This hyperexcitability phenotype of young neurons in bipolar disorder was selectively reversed by lithium treatment only in neurons derived from patients who also responded to lithium treatment."

The responder-selective rescue is what makes this node a candidate treatment-response stratifier rather than a generic cellular abnormality: the in-vitro correction tracks the donor's own clinical lithium response. It holds for the sampled lines and has not been shown to generalize across the heterogeneity of bipolar disorder.

Mitochondrial Dysfunction

Impaired cellular energy metabolism and oxidative stress affect neuronal function. Mitochondrial abnormalities linked to mood dysregulation.

Neuron CL:0000540

Oxidative phosphorylation GO:0006119 ⚠ ABNORMAL

Experimental models

Bipolar patient iPSC-derived hippocampal dentate gyrus-like neurons IPSC DERIVED MODEL The same neurons show mitochondrial differences from control neurons: higher expression of mitochondrial genes and a higher mitochondrial membrane potential.

Show evidence (3 references)

PMID:30285728 NO_EVIDENCE

"Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide."

This review discusses the molecular mechanisms underlying psychiatric disorders including bipolar disorder, with focus on the DISC1/GSK3 complex which regulates mitochondrial and cellular functions.

PMID:26524527 SUPPORT In Vitro

"Strikingly, we found that the expression of multiple mitochondria genes was significantly enhanced in the BD neurons"

RNA-seq of patient-derived dentate-gyrus-like neurons finds coordinated upregulation of mitochondrial genes, the first direct measurement supporting this node in patient-derived human neurons rather than by inference from review literature.

PMID:26524527 SUPPORT In Vitro

"Flow cytometry analysis revealed that BD neurons showed increased red/green ratios, indicative of enhanced mitochondrial function"

Note the direction: membrane-potential assay in young patient-derived neurons shows *enhanced* mitochondrial function, not the deficit the node description implies. Curated as a qualification -- the abnormality is established, but this study argues against reading it uniformly as impaired energy metabolism, consistent with the phasic model in which respiration is raised in mania and lowered in euthymia and depression.

Circadian Rhythm Disruption

Disrupted sleep-wake cycles and circadian gene expression contribute to mood instability. Sleep deprivation can trigger mania.

Neuron CL:0000540

Circadian Rhythm GO:0007623

Downstream

Monoamine Dysregulation Clock-gene disruption raises dopaminergic output. Evidence is a targeted rodent perturbation; no human circadian variant has been shown to drive dopaminergic change in bipolar patients, so the edge is model-organism grounded rather than established in human disease.

Show evidence (4 references)

PMID:22363263 NO_EVIDENCE

"For more than 60 years, the mood stabilizer lithium has been used alone or in combination for the treatment of bipolar disorder, schizophrenia, depression, and other mental illnesses."

This comprehensive review discusses lithium as the gold standard treatment for bipolar disorder, noting its mood-stabilizing effects through GSK3 inhibition which affects multiple cellular pathways including circadian regulation.

PMID:23919927 SUPPORT Model Organism

"these data suggest that GSK3β acts as a critical intrinsic regulator of the circadian clock and plays an important role in regulating its period in response to lithium treatment"

GSK3β haploinsufficiency lengthens circadian period in mice, mechanistically linking lithium's inhibition of GSK3β to its documented effects on circadian rhythm period and amplitude in bipolar disorder.

PMID:20591414 SUPPORT Model Organism

"We found that knockdown of Clock, specifically in the VTA, results in hyperactivity and a reduction in anxiety-related behavior, which is similar to the phenotype of the ClockDelta19 mice."

Region-restricted RNA-interference knockdown shows that disrupting a single core clock gene in one brain region is sufficient to produce mania-like behavior, which is the strongest causal support available for the circadian pillar of this model.

+ 1 more reference

Neuroplasticity Alterations

Reduced BDNF and altered synaptic plasticity in mood circuits. Lithium and other mood stabilizers enhance neuroplasticity.

Neuron CL:0000540

Synaptic Plasticity GO:0048167

Show evidence (3 references)

PMID:30285728 SUPPORT

"DISC1 binds directly to GSK3 and modulates many cellular functions by negatively inhibiting GSK3 activity."

GSK3 inhibition by DISC1 and mood stabilizers like lithium is a key mechanism in bipolar disorder treatment, affecting synaptic plasticity and neuronal survival pathways.

PMID:30285728 SUPPORT

"In the present review, we will focus on the emerging roles of TRAX and its interacting proteins (including DISC1 and GSK3β) in psychiatric disorders and the potential implications for developing therapeutic interventions."

The TRAX/DISC1/GSK3β complex is implicated in psychiatric disorders including bipolar disorder and represents a therapeutic target for enhancing neuroplasticity.

PMID:21743136 SUPPORT Other

"Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 activity and also to induce signaling mediated by brain-derived neurotrophic factor."

Lithium enhances neuroplasticity in part by inducing BDNF signaling and inhibiting GSK-3, directly complementing the reduced-BDNF pathophysiology captured in this node.

Neuroinflammation

Elevated inflammatory markers during mood episodes. Microglial activation and cytokine abnormalities contribute to pathophysiology.

Microglia CL:0000129

Inflammatory Response GO:0006954

Show evidence (1 reference)

PMID:33958577 NO_EVIDENCE

"considering that schizophrenia is a multifactorial and highly polygenic disorder that shares many risk genes with other psychiatric illnesses including bipolar disorder, depression, intellectual disability and autism spectrum disorders, it is to be expected that these diseases may also share..."

Microglial activation and inflammatory processes are shared pathophysiological mechanisms across psychiatric disorders including bipolar disorder, contributing to synaptic dysfunction.

GSK-3β Signaling Dysregulation

Glycogen synthase kinase-3β (GSK-3β) is a constitutively active serine/threonine kinase that phosphorylates β-catenin, tau, and numerous circadian and pro-apoptotic substrates. Excess GSK-3β activity is implicated in bipolar mood instability, and GSK-3β is the principal molecular target through which lithium is thought to exert its mood-stabilizing and neuroprotective effects. Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly (via the Akt / β-arrestin-2 / PP2A axis), stabilizing β-catenin and mimicking canonical Wnt signaling.

Neuron CL:0000540

Canonical Wnt Signaling GO:0060070 ↓ DECREASED

Downstream

Circadian Rhythm Disruption

Neuroplasticity Alterations

Show evidence (3 references)

PMID:8710892 SUPPORT Model Organism

"Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."

Klein and Melton identified GSK-3β as a direct molecular target of lithium in developmental model organisms — the foundational evidence for the GSK-3β hypothesis of lithium's action in bipolar disorder.

PMID:8710892 SUPPORT Model Organism

"Lithium potently inhibits GSK-3 beta activity (Ki = 2 mM), but is not a general inhibitor of other protein kinases."

Lithium inhibits GSK-3β at therapeutically relevant concentrations with selectivity over other protein kinases, supporting GSK-3β as a specific target.

PMID:8994831 SUPPORT In Vitro

"Li+ treatment of Drosophila S2 cells and rat PC12 cells induces accumulation of cytoplasmic Armadillo/beta-catenin, demonstrating that Li+ can mimic Wingless signalling in intact cells, consistent with its inhibition of GSK-3."

In intact mammalian (PC12) and insect cells, lithium inhibition of GSK-3 stabilizes β-catenin and reproduces canonical Wnt (Wingless) signaling, tying GSK-3β inhibition to a defined downstream pathway.

Phosphoinositide Signaling Dysregulation

Overactivity of the phosphatidylinositol (PIP2 / IP3) second-messenger cycle is implicated in bipolar mood instability (the "inositol depletion hypothesis"). The cycle regenerates free myo-inositol through inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase; lithium uncompetitively inhibits these Mg2+-dependent phosphatases, depleting free inositol and dampening the overactive signaling — a therapeutic target shared with valproate and carbamazepine. (The disease-state direction shown here is the overactive baseline; lithium's opposing, inhibitory action is captured on the Lithium treatment's target_mechanisms edge.)

Neuron CL:0000540

Inositol Phosphate Metabolism GO:0043647 ↑ INCREASED Phosphatidylinositol-Mediated Signaling GO:0048015 ↑ INCREASED

Show evidence (3 references)

PMID:12015604 SUPPORT Model Organism

"Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."

Williams et al. showed that lithium, valproate, and carbamazepine converge on inositol depletion — exogenous inositol rescues their shared cellular effect, direct evidence for the inositol-depletion mechanism.

PMID:12015604 SUPPORT Model Organism

"Berridge and colleagues suggested that inositol depletion may be the way that lithium works in bipolar affective disorder, but others have suggested that glycogen synthase kinase (GSK3) may be the relevant target."

Frames the two leading molecular hypotheses of lithium action — inositol depletion versus GSK-3 inhibition — both of which are curated as distinct pathophysiology nodes in this entry.

PMID:21743136 SUPPORT Other

"By inhibiting the activity of phosphoinositol phosphatases, it decreases levels of inositol 1,4,5-trisphosphate, a process recently identified as a novel mechanism for inducing autophagy."

Lithium inhibition of inositol phosphatases lowers IP3 and links inositol depletion to autophagy induction, a downstream neuroprotective consequence.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Manic Episodes VERY_FREQUENT Psychiatric HP:0100754

Elevated mood, decreased sleep, increased activity

Depressive Episodes VERY_FREQUENT Psychiatric HP:0000716

Show evidence (1 reference)

PMID:26388529 SUPPORT Human Clinical

"onset is most commonly a depressive episode and looks similar to unipolar depression"

Depressive episodes are the most common presenting mood state in bipolar disorder, frequently mimicking unipolar major depression.

Sleep Disturbance VERY_FREQUENT Psychiatric HP:0002360

Decreased need for sleep in mania, insomnia or hypersomnia in depression

Psychosis OCCASIONAL Psychiatric HP:0000709

Can occur in severe mania or depression

Anxiety FREQUENT Psychiatric HP:0000739

Cognitive Impairment FREQUENT Neurological HP:0100543

Executive function, attention deficits

Show evidence (1 reference)

PMID:23846857 SUPPORT

"All proband groups showed lower psychosocial functioning than the relatives or comparison group. On average, schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."

The B-SNIP study demonstrates that cognitive and psychosocial impairment is a consistent feature across psychotic disorders including bipolar disorder, though with varying severity.

🧬

Genetic Associations

7

CACNA1C (Risk Factor)

Gene: CACNA1C hgnc:1390 gene page

Show evidence (4 references)

PMID:18711365 SUPPORT

"We also found further support for the previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel; combined P = 7.0 x 10(-8), rs1006737)."

Landmark GWAS study providing genome-wide significant evidence that CACNA1C is a susceptibility locus for bipolar disorder, implicating calcium channel dysfunction in disease pathogenesis.

PMID:21057379 SUPPORT

"The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."

Case-case GWAS analysis further confirms the critical role of calcium channel genes including CACNA1C in bipolar disorder susceptibility.

PMID:25403839 SUPPORT DIRECT In Vitro

"we performed electrophysiology and quantitative PCR experiments that demonstrated increased L-type VGCC current density as well as increased mRNA expression of CACNA1C in iNs homozygous for the risk genotype, compared with non-risk genotypes"

Bridges the variant-to-function gap for the entry's flagship risk gene: induced human neurons from over 20 fibroblast lines show that the rs1006737 risk genotype raises CACNA1C transcript level and L-type calcium current density, fixing the direction of effect as gain of channel function. Scope caveat recorded by the authors themselves -- the rs1006737 haplotype is transdiagnostic and the donors included unaffected individuals, so this establishes a genotype-to-channel phenotype rather than a bipolar-specific circuit mechanism.

+ 1 more reference

ANK3 (Risk Factor)

Gene: ANK3 hgnc:494

Show evidence (1 reference)

PMID:18711365 SUPPORT

"To identify susceptibility loci for bipolar disorder, we tested 1.8 million variants in 4,387 cases and 6,209 controls and identified a region of strong association (rs10994336, P = 9.1 x 10(-9)) in ANK3 (ankyrin G)."

Genome-wide significant association of ANK3 with bipolar disorder in large-scale GWAS, establishing ankyrin G as a key susceptibility gene that may affect neuronal excitability and synaptic function.

ODZ4 (Risk Factor)

Show evidence (1 reference)

PMID:21926972 SUPPORT Human Clinical

"In particular, we support prior findings in CACNA1C, and now identify ODZ4 as associated with BD."

Psychiatric GWAS Consortium large-scale GWAS established genome-wide-significant association of the teneurin gene ODZ4 (TENM4) with bipolar disorder.

NCAN (Risk Factor)

Gene: NCAN hgnc:2465

Show evidence (1 reference)

PMID:21353194 SUPPORT Human Clinical

"Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with BD"

GWAS with independent replication identified the extracellular-matrix glycoprotein gene NCAN (neurocan) as a genome-wide-significant bipolar disorder susceptibility locus.

SETD1A (Candidate risk factor (founder-population missense allele; nominal association, not yet replicated))

Gene: SETD1A hgnc:29010 gene page relationship_type: SUSCEPTIBILITY

Show evidence (3 references)

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT Human Clinical

"was associated with a 1.8-fold relative risk for BD in our sample (P = 0.027; Fig. 1A)."

The primary bipolar-disorder association, quoted with its effect size and p-value rather than from the abstract. The effect is nominal (P = 0.027, uncorrected), confined to a single founder population, and reported in a non-peer-reviewed preprint, so this is recorded as a lead rather than an established locus - see the linked knowledge gap for what replication would require.

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT Human Clinical

"homozygotes performing worse than heterozygotes, especially on the Verbal Memory subtest."

An allele-dose-dependent quantitative phenotype in adult carriers, which is a stronger genetic argument than the diagnostic association itself because it does not depend on case ascertainment.

PMID:26974950 SUPPORT Human Clinical

"Together, our observations indicate that LoF variants in SETD1A cause a range of neurodevelopmental disorders, including schizophrenia."

Peer-reviewed context for the gene, not for the bipolar association: SETD1A disruption already spans a range of neurodevelopmental diagnoses, which is the prior that makes a mood-disorder association plausible enough to record. It does not itself implicate SETD1A in bipolar disorder.

Variants (1)

SETD1A p.Pro596Leu (rs139187973)

missense variant

A missense substitution outside the catalytic SET domain, at 5.2% allele frequency in the Lancaster Old Order Amish versus 0.09% in gnomAD exomes. Patient-derived iPSCs homozygous for the allele show signatures of SETD1A hypofunction rather than a clean null, so the allele is best read as a hypomorph rather than as equivalent to the loss-of-function alleles that drive the schizophrenia association.

Functional effects

histone H3K4 methyltransferase activity loss-of-function

Homozygous carrier iPSCs proliferate more slowly and are markedly more susceptible to hydroxyurea-induced DNA double-strand breaks; the proliferation deficit is rescued by overexpression of reference-sequence SETD1A, and neurite and senescence phenotypes are partially rescued by inhibiting the opposing H3K4 demethylase KDM5.

Show evidence (2 references)

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT Human Clinical

"Exome sequencing (n = 3,736) revealed a population-enriched SETD1A missense variant (P596L) in the Lancaster Old Order Amish founder population, presenting a unique opportunity to elucidate variant-specific, multi-scale mechanisms."

Establishes the founder-population enrichment that makes this specific allele tractable, and the reason it is not informative about bipolar-disorder risk in the general population.

PPR:PPR1277941 Preprint · not peer-reviewed SUPPORT In Vitro

"Induced pluripotent stem cells (iPSCs) from homozygous carriers exhibited signatures of SETD1A hypofunction, including reduced proliferation and heightened susceptibility to replication stress and DNA double-strand breaks."

Sources the hypomorph reading of the allele - patient-derived cells show reduced SETD1A function with genome-instability consequences rather than a null phenotype.

ITIH3 (Risk Factor)

Gene: ITIH3 hgnc:6168 gene page relationship_type: SUSCEPTIBILITY

Show evidence (2 references)

PMID:34002096 SUPPORT Human Clinical

"9c 3 52626443 rs2336147 3.6 × 10−13 1.070 0.009 T/C 0.498 ITIH1 (PGC2) SCZ, CDG"

Table 1 row from the PGC bipolar disorder GWAS (41,917 cases): locus 9, index SNP rs2336147 at chr3:52,626,443 (GRCh37; 3p21.1), P = 3.6 x 10^-13, OR 1.070, named by the authors for ITIH1 and previously reported for schizophrenia and by the Cross-Disorder Group. This is the peer-reviewed genome-wide-significant bipolar association at the ITIH-cluster locus; the index SNP itself sits proximal to the ITIH genes rather than within them.

PPR:PPR1294131 Preprint · not peer-reviewed SUPPORT Computational

"ConjFDR analysis revealed 2,143 pleiotropic SNPs jointly associated with BIP and OCD, with convergent signals at the ITIH3/ITIH4 locus."

Cross-trait conjunctional-FDR analysis of bipolar disorder and OCD GWAS summary statistics converges on the ITIH3/ITIH4 locus. PARTIAL because this is a non-peer-reviewed preprint and a summary-statistics analysis: it prioritizes ITIH3/ITIH4 among the genes at 3p21.1 but does not experimentally establish either gene as the effector.

AKAP11 (Risk Factor)

relationship_type: RISK_FACTOR

Show evidence (3 references)

PMID:35410376 SUPPORT Human Clinical

"Combining gene-level results with SCHEMA, AKAP11 emerges as a definitive risk gene"

Whole-exome sequencing of 13,933 bipolar cases and 14,422 controls establishes AKAP11 as a bipolar risk gene. The qualification is in the sentence itself: the definitive gene-level result requires combining BipEx with the schizophrenia SCHEMA analysis, so this is a cross-disorder rather than bipolar-specific finding.

PMID:35410376 SUPPORT INDIRECT Human Clinical

"At the protein level, AKAP-11 interacts with GSK3B, the hypothesized target of lithium, a primary treatment for BD."

The basis for reading AKAP11 as independent rare-variant convergence on the GSK-3 beta pillar of this model. Graded INDIRECT because the link is a protein-protein interaction reported by the same paper, not a demonstration that AKAP11 truncating variants change GSK3B activity in patients.

PMID:35410376 SUPPORT Human Clinical

"Genes implicated from genome-wide association studies (GWASs) of BD, however, are not significantly enriched for ultra-rare PTVs."

Records that the common-variant loci curated above (CACNA1C, ANK3, ODZ4, NCAN, the 3p21.1 region) are not the genes carrying the rare truncating burden, so the polygenic common-variant architecture and the rare-variant architecture are at least partly separate rather than two readouts of one gene set.

💊

Medical Actions

7

Lithium

Action: Pharmacotherapy NCIT:C15986

Agent: lithium carbonate CHEBI:6504

Platform: Small molecule

First-line mood stabilizer, effective for mania and suicide prevention.

Mechanism Target:

INHIBITS GSK-3β Signaling Dysregulation — Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly (via Akt / β-arrestin-2 / PP2A), stabilizing β-catenin and mimicking canonical Wnt signaling — the principal proposed molecular basis of its mood-stabilizing effect.

Show evidence (1 reference)

PMID:8710892 SUPPORT Model Organism

"Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."

Direct evidence that lithium acts by inhibiting GSK-3β.

INHIBITS Phosphoinositide Signaling Dysregulation — Lithium uncompetitively inhibits inositol monophosphatase and related phosphatases, depleting free inositol and dampening PIP2 / IP3 signaling.

Show evidence (1 reference)

PMID:12015604 SUPPORT Model Organism

"Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."

Inositol rescue implicates inositol depletion as a mechanism of lithium action.

MODULATES Circadian Rhythm Disruption — Through GSK-3β inhibition lithium lengthens circadian period and stabilizes clock-gene rhythm amplitude, addressing circadian instability in bipolar disorder.

MODULATES Neuroplasticity Alterations — Lithium induces BDNF signaling and upregulates neurotrophic/neuroprotective pathways, enhancing synaptic plasticity in fronto-limbic mood circuits.

Show evidence (2 references)

PMID:41672966 SUPPORT INDIRECT Human Clinical

"Across modalities, lithium treatment was most consistently associated with larger volumes in the hippocampus, amygdala, anterior cingulate cortex (ACC), and prefrontal cortex (PFC), and with higher white-matter integrity within frontolimbic circuitry."

Locates lithium's structural association in exactly the fronto-limbic regions this model names, at the circuit level rather than the molecular level. Graded INDIRECT deliberately: a volume association is an inference step away from the plasticity mechanism this edge asserts.

PMID:41672966 SUPPORT Human Clinical

"Overall risk of bias was substantial, yielding low-to-moderate certainty of evidence."

The review's own certainty rating, curated alongside its headline result so the edge is not read as established causation. 78 of the 115 included studies were cross-sectional and only six were randomized, so the design base cannot separate a protective drug effect from confounding by who stays on lithium.

Show evidence (5 references)

PMID:22363263 SUPPORT

"Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"

Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition.

PMID:22363263 SUPPORT

"In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."

Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects.

PMID:21743136 SUPPORT Other

"By inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, for instance, it suppresses the calcium-dependent activation of pro-apoptotic signaling pathways."

Beyond GSK-3β and inositol depletion, lithium contributes to neuronal calcium homeostasis by limiting NMDA-receptor calcium influx and downstream pro-apoptotic signaling.

+ 2 more references

Valproate

Mood stabilizer, effective for mania.

Show evidence (1 reference)

PMID:11473107 SUPPORT In Vitro

"Valproic acid is widely used to treat epilepsy and bipolar disorder"

Establishes valproate as a mood stabilizer used in bipolar disorder and identifies histone deacetylase inhibition as a molecular mechanism of action.

Lamotrigine

Mood stabilizer, more effective for depression prevention.

Atypical Antipsychotics

Quetiapine, olanzapine, aripiprazole for mania and maintenance.

Antidepressants

Used cautiously with mood stabilizer to prevent switch to mania.

Psychotherapy

CBT, interpersonal therapy, psychoeducation. Interpersonal and social rhythm therapy (IPSRT) is the arm that bears on this entry's circadian mechanism: it adds an explicit social-rhythm regulation component to interpersonal psychotherapy, and is the closest thing to a clinical test of whether stabilizing daily rhythms alters the course of bipolar disorder.

Mechanism Target:

MODULATES Circadian Rhythm Disruption — IPSRT regularizes sleep and social routines, and greater achieved regularity during acute treatment tracks lower recurrence in maintenance. This is an association within a randomized trial rather than a demonstrated causal pathway: IPSRT is multicomponent, so the benefit cannot be attributed to the circadian component alone, and the social-rhythm analysis is mediational rather than a direct circadian perturbation.

Show evidence (1 reference)

PMID:16143731 SUPPORT INDIRECT Human Clinical

"Ability to increase regularity of social rhythms during acute treatment was associated with reduced likelihood of recurrence during the maintenance phase (P = .05)."

The specific result linking rhythm regularity to clinical course, and so the only clinical evidence in this entry bearing on the circadian node as a modifiable target. Graded INDIRECT because it is an association between an achieved process measure and outcome, not a randomized manipulation of circadian timing.

Show evidence (3 references)

PMID:16143731 SUPPORT Human Clinical

"participants assigned to IPSRT in the acute treatment phase survived longer without a new affective episode (P = .01), irrespective of maintenance treatment assignment"

Randomized trial in 175 acutely ill bipolar I patients showing that acute phase IPSRT lengthened time to a new episode over two years of maintenance. Note the scope: patients entered acutely ill rather than euthymic, so this is not the prevention-from-euthymia trial the entry's chronotherapy gap refers to.

PMID:16143731 SUPPORT Human Clinical

"We observed no difference between the treatment strategies in time to stabilization."

Curated alongside the positive result to keep the claim bounded: IPSRT did not speed acute stabilization, and its benefit in this trial was confined to prophylaxis against later episodes.

PMID:26388529 SUPPORT Human Clinical

"the evolving pharmacological and psychological strategies in bipolar disorder is of utmost importance"

This clinical review emphasizes psychological (psychotherapeutic) strategies alongside pharmacotherapy as core to bipolar disorder management.

ECT

For severe or treatment-resistant episodes.

🌍

Environmental Factors

4

Childhood Trauma

Increases risk

Show evidence (1 reference)

PMID:33364762 SUPPORT Human Clinical

"individuals with BD are 2.63 times more likely to report CT compared to healthy individuals"

Review quantifies childhood trauma as a risk factor for bipolar disorder, with individuals with BD reporting childhood trauma at 2.63 times the rate of healthy individuals.

Sleep Deprivation

Can trigger manic episodes

Show evidence (1 reference)

PMID:10482346 SUPPORT Human Clinical

"we observed a 4.85% switch rate into mania and a 5.83% switch rate into hypomania"

Clinical trial of therapeutic sleep deprivation in 206 bipolar depressed patients measured the switch into mania (4.85%) and hypomania (5.83%), quantifying sleep loss as a trigger of manic episodes.

Substance Use

Comorbid and can trigger episodes

Show evidence (2 references)

PMID:34833474 SUPPORT Human Clinical

"Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes"

PARTIAL: this supports the comorbidity half of the annotation and an effect on clinical course, but not the episode-triggering half. The same review notes it is still unclear why bipolar patients are at higher risk of addictive disorders, so the direction of that relationship is not settled.

PMID:27476137 SUPPORT Human Clinical

"The SUDs with the highest prevalence in BD were alcohol use (42%) followed by cannabis use (20%) and other illicit drug use (17%)"

Systematic review and meta-analysis quantifies the high prevalence of comorbid substance use disorders in bipolar disorder.

Stress

Life events can precipitate episodes

Show evidence (2 references)

PMID:24751308 SUPPORT Human Clinical

"Negative life events were significantly associated with both subsequent severity of mania and depressive symptoms and functional impairment"

Prospective study of 173 bipolar outpatients assessed quarterly for two years. PARTIAL because the same study found the reverse direction as well -- depressive symptoms preceded negative life events, and manic symptoms preceded positive ones -- so its own title asks whether life events are cause or consequence, and its authors state the design cannot settle that.

PMID:36940629 SUPPORT Human Clinical

"possible triggers including fasting, decreased sleep and stressful life events"

Systematic review of triggers for acute mood episodes in bipolar disorder identifies stressful life events among triggers for depressive relapse.

🔬

Biochemical Markers

3

BDNF (Decreased)

Context: Reduced in both manic and depressive episodes

Cortisol (Elevated)

Context: HPA axis dysregulation

Inflammatory Markers (Elevated)

Context: IL-6, TNF-alpha during episodes

🔬

Diagnosis

1

Mood Disorder Questionnaire screening

The Mood Disorder Questionnaire (MDQ) is a brief self-report screening instrument for bipolar spectrum disorder. A positive screen identifies patients for diagnostic interview; it does not establish the diagnosis. Its panel code identifies the instrument and its total-score code carries the screening threshold.

bipolar disorder screening NCIT:C15419

MDQ LOINC:85102-2

Reference Ranges

Total score [MDQ] (198 patients attending five outpatient clinics that primarily treat mood disorders, against the bipolar module of the Structured Clinical Interview for DSM-IV (Hirschfeld et al. 2000))

Below the screening threshold (0–7 {score}) Screening threshold met (7 or more items) (≥ 7 {score})

The source states "A Mood Disorder Questionnaire screening score of 7 or more items yielded good sensitivity (0.73) and very good specificity (0.90)", so 7 is the inclusive lower bound of the upper band. The band records that item-count threshold exactly as the abstract states it and nothing more; any further conditions the instrument's scoring instructions attach to a positive screen are not in the cited abstract and are not recorded here. In a general-population validation led by the same first author, the MDQ showed sensitivity 0.281 and specificity 0.972 (PMID:12505821, whose abstract does not state the threshold used), so the instrument's operating characteristics depend on setting.

Show evidence (1 reference)

PMID:11058490 SUPPORT Human Clinical

"A Mood Disorder Questionnaire screening score of 7 or more items yielded good sensitivity (0.73) and very good specificity (0.90)."

States the screening threshold recorded as the lower bound of the upper band.

Show evidence (2 references)

PMID:11058490 SUPPORT Human Clinical

"The Mood Disorder Questionnaire is a useful screening instrument for bipolar spectrum disorder in a psychiatric outpatient population."

The validation study's conclusion supporting the MDQ as a bipolar spectrum screening instrument in psychiatric outpatients.

PMID:12505821 SUPPORT Human Clinical

"The operating characteristics of the Mood Disorder Questionnaire in the general population differ substantially from its characteristics in outpatient psychiatric settings."

A general-population validation showing that the instrument's accuracy differs by setting, which qualifies how a positive screen is read.

📊

Related Datasets

9

Choroid plexus inflammation in bipolar disorder geo:GSE328018

Postmortem human choroid plexus tissue from individuals with bipolar disorder and matched controls was analyzed using cytokine protein arrays and bulk RNA sequencing to characterize immune and barrier-related alterations. The study identifies increased pro-inflammatory signaling and reduced trophic/supportive pathways, implicating the choroid plexus as a neuroimmune interface in bipolar disorder.

human BULK RNA SEQ n=23

PMID:41980683

Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.

Single-nucleus RNA sequencing in the post-mortem thamaus and cortex in bipolar disorder geo:GSE306819

We performed high-throughput single-nucleus RNA sequencing (snRNA-seq) using the 10x Genomics Chromium platform on archived postmortem thalamus and frontal cortex (BA10) tissues from patients with bipolar disorder and control subjects to identify cell type–specific differentially expressed genes and compositional changes.

human SINGLE CELL RNA SEQ n=82

PMID:41501055

Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.

Differential effects of lithium on metabolic dysfunction in astrocytes derived from bipolar disorder patients geo:GSE241671

Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by biphasic mood episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes in BD patients remain largely unknown and have not been extensively studied. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients and their responses to lithium treatment. The gene expression profiles of iAstrocytes from BD patients (BD iAstrocytes) indicate dysregulation of metabolic processes in BD iAstrocytes.

human BULK RNA SEQ n=30

PMID:40847005

Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.

WTCCC case-control study for Bipolar Disorder ega:EGAS00000000001

WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

WTCCC case-control study for Bipolar Disorder - Combined Controls ega:EGAS00000000002

WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Exome sequencing in bipolar disorder families ega:EGAS00001003085

Bipolar disorder (BD) is a major psychiatric disorder affecting around 1% of the global population. BD is characterized by recurrent manic and depressive episodes, and has an estimated heritability of around 70% Research has identified the first BD susceptibility genes. However, the underlying pathways and regulatory networks remain largely unknown. Since research has shown that the cumulative impact of common alleles with small effect appears to explain only around 25-38% of the phenotypic variance for BD, rare variants of high penetrance may also contribute to BD risk.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Bipolar disorder metabolomics analysis using FiehnLib and GMD for curation metabolomics_workbench:ST001946

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.

Dysregulation of the complement and coagulation cascade in treated schizophrenia and bipolar disorder patients massive:MSV000086425

A better understanding of the proteomic profile after bipolar disorder (BD) and schizophrenia (SCZ) treatment, through monitoring its progression, may assist the development of novel therapeutic strategies with the ability to reduce or control possible side effects. In this study, proteomics analysis employing liquid chromatography coupled to mass spectrometry (LC-MS) and bioinformatic tools were applied to identify differentially expressed proteins in serum of treated BD and SCZ patients. In total, 10 BD patients, 10 SCZ patients, and 14 healthy participants were included.

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.

Family Genomics of Bipolar Disorder dbgap:phs000866

This study examined the segregation of variants with phenotype in pedigrees harboring bipolar disorder.

Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.

🧫

Experimental Models

1

Bipolar patient iPSC-derived hippocampal dentate gyrus-like neurons IPSC_DERIVED_MODEL

Hippocampal dentate gyrus granule cell-like neurons differentiated from induced pluripotent stem cells of six patients with bipolar I disorder and four unaffected individuals. Three of the patients responded to lithium in a clinical trial and three did not. This is the only patient-derived model in this entry. The neurons were studied at three weeks of differentiation, with and without one week of 1 mM lithium chloride.

Organism

human NCBITaxon:9606

Cell source

Induced pluripotent stem cells reprogrammed from skin fibroblasts of six patients with bipolar I disorder and four unaffected individuals, two clones per person. Patient-derived.

Publication

PMID:26524527

Pathograph links

Neuronal Hyperexcitability recapitulates fidelity: moderate observes: cellular Neurons from patients fire action potentials more readily than neurons from unaffected individuals. Lithium reverses the difference only in neurons from patients who responded to lithium clinically. This node was curated from this study.

Limitations: Six patients, all white men with bipolar I disorder recruited from lithium monotherapy trials, and one neuron type. The hyperexcitability was seen in three-week-old neurons and reversed as the neurons aged. No experiment shows that it causes mood episodes. Fidelity is MODERATE because the cells are patient-derived and human, but the finding has not been matched to a measurement in patients' brains.

Divergences from the human mechanism

population mismatch qualifying

The six donors are white men with manic bipolar I disorder from lithium monotherapy trials. The entry covers bipolar disorder of all types, in all patients.

temporal scope qualifying

The readout is from neurons three weeks into differentiation. The authors report that the hyperexcitability reverses in older neurons, so the finding describes young neurons in culture and not a stable state.

boundary omission qualifying

The culture is mostly one neuron type. Other hippocampal cell types, long-range inputs and mood circuits are absent, so the model shows a cell-intrinsic property and cannot show its effect on circuit activity.

Readouts

Action-potential firing (patch-clamp recording and calcium imaging)

Action Potential Firing GO:0001508

Direction: INCREASED

Interpretation: Higher in neurons from patients than in neurons from unaffected individuals.

Show evidence (1 reference)

PMID:26524527 SUPPORT PRIMARY RESULT In Vitro

"using both patch-clamp recording and somatic Ca(2+) imaging, we have observed hyperactive action-potential firing"

The primary electrophysiology and imaging result.

Action-potential firing after lithium, in neurons from clinical lithium responders

Action Potential Firing GO:0001508

Direction: RESTORED

Interpretation: Lithium lowered firing toward the control level in neurons from responders and had no clear effect in neurons from non-responders.

Show evidence (1 reference)

PMID:26524527 SUPPORT PRIMARY RESULT In Vitro

"This hyperexcitability phenotype of young neurons in bipolar disorder was selectively reversed by lithium treatment only in neurons derived from patients who also responded to lithium treatment."

Reports the reversal and that it was limited to responders' neurons.

Show evidence (1 reference)

PMID:26524527 SUPPORT PRIMARY RESULT In Vitro

"hyperexcitability is one early endophenotype of bipolar disorder"

The authors' conclusion that the phenotype seen in patient-derived neurons belongs to the disorder.

Mitochondrial Dysfunction measures fidelity: unknown observes: cellular The same neurons show mitochondrial differences from control neurons: higher expression of mitochondrial genes and a higher mitochondrial membrane potential.

Limitations: The direction is the opposite of the impairment this node describes. Young patient-derived neurons show enhanced mitochondrial function, so the model supports a mitochondrial abnormality and does not support reading it as an energy deficit. The same donor and cell-type limits apply as for the hyperexcitability link.

Readouts

Mitochondrial membrane potential (flow cytometry, red/green ratio)

Direction: INCREASED

Interpretation: Higher in neurons from patients than in control neurons, which the authors read as enhanced mitochondrial function.

Show evidence (1 reference)

PMID:26524527 SUPPORT PRIMARY RESULT In Vitro

"Flow cytometry analysis revealed that BD neurons showed increased red/green ratios, indicative of enhanced mitochondrial function"

The membrane-potential measurement and its direction.

{ }

Source YAML

click to show

name: Bipolar Disorder
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Bipolar disorder is a chronic psychiatric mood disorder characterized by
  recurrent episodes of mania or hypomania alternating with depression. Subtypes
  include bipolar I (full manic episodes), bipolar II (hypomania with major
  depression), and cyclothymic disorder. Its pathophysiology involves
  dysregulation of monoaminergic neurotransmission, mitochondrial and cellular
  energetics dysfunction, and disturbances of circadian and neuroplasticity
  signaling.
category: Complex
parents:
- Psychiatric Disease
disease_term:
  preferred_term: bipolar disorder
  term:
    id: MONDO:0004985
    label: bipolar disorder
has_subtypes:
- name: Bipolar I Disorder
  description: Characterized by manic episodes, with or without depressive episodes.
  evidence:
  - reference: PMID:31043756
    reference_title: "Genome-wide association study identifies 30 loci associated with bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis"
    explanation: Large GWAS shows bipolar I disorder is genetically distinguished from bipolar II by its strong correlation with schizophrenia and psychosis.
- name: Bipolar II Disorder
  description: Characterized by hypomanic and depressive episodes, no full mania.
  evidence:
  - reference: PMID:31043756
    reference_title: "Genome-wide association study identifies 30 loci associated with bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bipolar II disorder is more strongly correlated with major depressive disorder"
    explanation: GWAS genetic-correlation analysis distinguishes bipolar II disorder from bipolar I by its stronger correlation with major depressive disorder.
- name: Cyclothymic Disorder
  description: Chronic fluctuating mood with hypomanic and depressive symptoms.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_polygenic_synaptic_circadian_dysregulation_model
  hypothesis_label: Canonical Polygenic / Synaptic / Circadian Dysregulation Model
  status: CANONICAL
  description: >-
    Bipolar disorder is a highly heritable polygenic mood disorder in which common variants in CACNA1C,
    ANK3, ODZ4, and other ion-channel and synaptic genes combine with circadian/clock gene variants
    (CLOCK, BMAL1, NR1D1) to produce episodic mood instability. Mitochondrial dysfunction, calcium-signaling
    dysregulation, and altered neuroplasticity in fronto-limbic circuits (anterior cingulate,
    amygdala, ventral striatum) drive cycling between depressive and manic states. Lithium's mood-stabilizing
    efficacy (targeting GSK-3β / inositol monophosphatase / circadian amplitude),
    valproate's modulation of histone deacetylases, and the recurrent involvement of the dopaminergic
    reward system during manic episodes corroborate the polygenic-synaptic-circadian framework as the
    canonical model.
  notes: >-
    Retained as CANONICAL with six explicit
    qualifications, independently re-verified against the cited
    primary sources rather than the 2026 openscientist
    hypothesis-search report's framing
    (kb/hypotheses/Bipolar_Disorder/canonical_polygenic_synaptic_circadian_dysregulation_model),
    which finds PARTIALLY SUPPORTED. Each major pillar — common
    ion-channel / synaptic gene variants (CACNA1C, ANK3, ODZ4),
    circadian/clock variants, mitochondrial dysfunction, calcium
    signaling, and fronto-limbic neuroplasticity — has
    substantial GWAS, iPSC, animal-model, and pharmacological
    support, with lithium and valproate efficacy and dopaminergic
    mania consistent with the model. The 2025 multi-ancestry PGC4
    GWAS (298 genome-wide-significant loci across 158,036 cases
    and 2.8 million controls, PMID:39843750) is the current
    largest genetic-architecture study of BD and supersedes the
    smaller PGC3 scan the report's genetics framing was based on.
    Six qualifications, each rescoped to what its cited study
    actually shows: (1) postmortem cortical transcriptome data
    (PMID:33442739) show a less-pronounced, psychosis-concentrated
    similarity between schizophrenia and BD gene-expression
    alterations — the study never tested the canonical
    calcium/circadian/synaptic model and did not restrict its BD
    sample to BD-I, so it qualifies rather than establishes that
    the model "best explains psychotic BD-I"; (2) the
    calcium-channel-blocker translational picture is a small,
    unresolved lead rather than a demonstrated
    dihydropyridine-vs-verapamil subclass effect — the decisive
    verapamil-to-dihydropyridine (nimodipine, then isradipine)
    response switch involved only two bipolar patients embedded in
    a 30-person mixed unipolar/bipolar refractory-affective-illness
    cohort (PMID:9790159), and a broader review of calcium-channel
    antagonist trials in BD found only limited support for efficacy
    (PMID:11252650); (3) lithium response pharmacogenomics
    implicates PI3K-Akt / focal-adhesion pathways rather than direct
    GSK-3β (partially reconcilable via the PI3K→Akt→GSK-3β cascade);
    (4) TIMELESS and RORA are circadian-gene leads from a single 2014
    candidate-gene association study (353 SNPs across 21 circadian
    genes, meta-analysed across two internal BD cohorts,
    PMID:24716566), not an update established across the modern GWAS
    literature, so they supplement rather than displace CLOCK/BMAL1
    as canonical circadian candidates; (5) the claim that
    BD-risk-gene-attributed structural abnormalities are shared
    across the psychosis spectrum conflates two weaker, separate
    findings — a candidate-SNP imaging study of CACNA1C/ANK3/ODZ4/SYNE1
    found no risk-variant-structural association surviving
    multiple-testing correction (PMID:23820096), so there is no
    confirmed gene-attributed structural finding to generalize from,
    and a separate ENIGMA mega-/meta-analysis found shared
    cortical/subcortical abnormalities across BD, schizophrenia, major
    depressive disorder, and OCD generally (PMID:32646651) — a
    transdiagnostic pattern, not one specific to a psychosis spectrum
    or tied to risk-gene status; (6) critical experiments remain
    largely unperformed — no GSK-3β-selective inhibitor trial and no
    chronotherapy prevention trial from euthymia exist as of 2026, and
    while a modern dihydropyridine CCB trial was registered (adjunctive
    isradipine for bipolar depression, NCT01784666), it was terminated
    early for lack of enrollment (2 participants), so an adequately
    powered modern DHP-CCB trial remains a real gap rather than one
    that was never attempted.
  evidence:
  - reference: PMID:21057379
    reference_title: "Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
  - reference: PMID:33442739
    reference_title: "Similarities in Cortical Transcriptome Alterations Between Schizophrenia and Bipolar Disorder Are Related to the Presence of Psychosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "correlation analyses showed that BP subjects had similar, although less pronounced, gene expression alterations"
    explanation: >
      Postmortem cortical transcriptome comparison finds BD subjects
      share schizophrenia-like gene-expression alterations, but only
      less pronounced ones concentrated among BD subjects with
      psychosis. The case-control study did not test the canonical
      calcium/circadian/synaptic model directly and did not restrict
      its BD sample to BD-I, so it qualifies rather than establishes
      that the model "best explains psychotic BD-I."
  - reference: PMID:9790159
    reference_title: "Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two BP patients failed to maintain improvement but responded again to nimodipine and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine"
    explanation: >
      The decisive verapamil-to-dihydropyridine response switch cited
      for the pharmacological-subclass hypothesis involved only two
      bipolar patients within a 30-person mixed-diagnosis
      refractory-affective-illness cohort — a small case-series lead,
      not a demonstrated subclass effect.
  - reference: PMID:11252650
    reference_title: "Calcium channel antagonists for the treatment of bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "concluding there is presently limited support for their efficacy"
    explanation: >
      Review of calcium-channel-antagonist trials in bipolar disorder
      concludes that more recent, better-controlled studies found only
      limited support for efficacy, tempering the
      calcium-channel-blocker translational-failure claim.
  - reference: PMID:24716566
    reference_title: "Association between circadian genes, bipolar disorders and chronotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TIMELESS and RORA genes may confer susceptibility to BD and impact on circadian"
    explanation: >
      Single 2014 candidate-gene association study (353 SNPs across 21
      circadian genes, meta-analysed across two internal BD cohorts)
      finds TIMELESS and RORA variants associated with BD. This is a
      circadian-gene lead from one study design, not a modern
      literature-wide meta-analytic replacement for CLOCK/BMAL1
      priority.
  - reference: PMID:23820096
    reference_title: "No evidence for association between bipolar disorder risk gene variants and brain structural phenotypes."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "these risk SNPs do not explain a large proportion of the structural brain alterations in BD"
    explanation: >
      Candidate-SNP imaging study of CACNA1C, ANK3, ODZ4, and SYNE1
      found no risk-variant-structural association surviving
      multiple-testing correction, refuting the premise that structural
      brain abnormalities are attributed to BD risk genes in the first
      place.
  - reference: PMID:32646651
    reference_title: "Cross-Disorder Analysis of Brain Structural Abnormalities in Six Major Psychiatric Disorders: A Secondary Analysis of Mega- and Meta-analytical Findings From the ENIGMA Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain structural abnormalities in major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder were highly correlated"
    explanation: >
      ENIGMA mega-/meta-analysis finds shared cortical/subcortical
      abnormality patterns across BD, schizophrenia, major depressive
      disorder, and obsessive-compulsive disorder generally — a
      transdiagnostic pattern, not one specific to a psychosis spectrum
      or tied to BD-risk-gene status.
  - reference: clinicaltrials:NCT01784666
    reference_title: "Adjunctive Isradipine for the Treatment of Bipolar Depression"
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: 'Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsychotics for individuals currently experiencing a major depressive episode.'
    explanation: >
      A modern adjunctive-isradipine (dihydropyridine L-type CCB) trial
      for bipolar depression was registered, refuting a categorical "no
      modern dihydropyridine CCB trial" claim. ClinicalTrials.gov
      records it as Terminated for lack of enrollment (2 participants),
      so an adequately powered modern DHP-CCB trial remains a real gap
      rather than one never attempted.
  - reference: PMID:39843750
    reference_title: "Genomics yields biological and phenotypic insights into bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We analysed data from participants of European, East Asian, African American and Latino ancestries (n = 158,036 cases with bipolar disorder, 2.8 million controls)"
    explanation: >
      The 2025 multi-ancestry PGC4 GWAS (298 genome-wide-significant
      loci) is the current largest genetic-architecture study of BD,
      updating the polygenic-risk-locus evidence base beyond the
      smaller PGC3 scan the 2026 hypothesis-search report's genetics
      framing was based on.
  - reference: PMID:34002096
    reference_title: "Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bipolar disorder risk alleles were enriched in genes in synaptic signaling pathways and brain-expressed genes, particularly those with high specificity of expression in neurons of the prefrontal cortex and hippocampus."
    explanation: >
      Genome-wide, hypothesis-free pathway enrichment is the strongest
      unbiased support for the synaptic pillar of this model: the risk
      alleles concentrate in synaptic-signaling genes expressed in
      prefrontal-cortex and hippocampal neurons rather than being spread
      across brain-expressed genes generally.
  - reference: PMID:34002096
    reference_title: "Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant signal enrichment was found in genes encoding targets of antipsychotics, calcium channel blockers, antiepileptics and anesthetics."
    explanation: >
      Drug-target enrichment ties the polygenic signal to the calcium and
      ion-channel pharmacology named by this model. Note the enrichment is
      shared with antipsychotic, antiepileptic and anesthetic targets, so it
      supports ion-channel involvement broadly rather than singling out
      L-type calcium channels.
pathophysiology:
- name: Monoamine Dysregulation
  description: >
    Imbalances in dopamine, norepinephrine, and serotonin neurotransmission
    contribute to mood episodes. Elevated dopamine in mania, reduced in
    depression.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  - preferred_term: Noradrenergic Neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
  biological_processes:
  - preferred_term: Neurotransmitter Signaling
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "Activation of the dopamine receptor 2 (D2R) has been shown to stimulate the inactivation of Akt by PP2A (Beaulieu et al., 2005; Beaulieu and Gainetdinov, 2011), therefore providing a mechanism through which GPCR activation can inhibit Akt in response to extracellular signals."
    explanation: Dopamine D2 receptor signaling regulates the Akt/GSK3 pathway, providing a molecular link between monoaminergic neurotransmission and mood regulation in bipolar disorder.
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "This mechanism of D2R signaling appears to play important roles in the regulation of locomotor behavior and sensory motor gating by dopamine (Beaulieu et al., 2004; Emamian et al., 2004). It could also contribute to the therapeutic and/or adverse effects of psychoactive drugs like amphetamines and antpsychotics that act on dopamine neurotransmission"
    explanation: The D2 receptor-mediated regulation of GSK3 activity through beta-arrestin signaling is implicated in behavioral regulation relevant to bipolar disorder and the mechanism of mood stabilizers and antipsychotics.
- name: Intracellular Calcium Dysregulation
  biological_scale: CELLULAR
  description: >
    Altered intracellular calcium handling is among the oldest and most
    replicated cellular findings in bipolar disorder: basal and stimulated
    cytosolic calcium are elevated in patient platelets and lymphocytes, and
    endoplasmic-reticulum calcium release through the IP3 receptor is enhanced
    in patient lymphoblasts carrying the low-expressing BCL2 rs956572 AA
    genotype. This is the cellular counterpart of the calcium-channel genetics
    curated under CACNA1C. Two scope limits are load-bearing and should not be
    read past: the replicated measurements are in peripheral blood cells rather
    than neurons, and they have not been shown to track mood state over time --
    the original series found little correlation between calcium measures and
    mood-rating severity. The node therefore records a trait-associated
    calcium abnormality, not a demonstrated driver of episode switching (see
    the attached knowledge gap).
  biological_processes:
  - preferred_term: Intracellular Calcium Homeostasis
    term:
      id: GO:0006874
      label: intracellular calcium ion homeostasis
    modifier: ABNORMAL
  - preferred_term: IP3 Receptor-Mediated ER Calcium Release
    term:
      id: GO:0051209
      label: release of sequestered calcium ion into cytosol
    modifier: INCREASED
  evidence:
  - reference: PMID:10418700
    reference_title: "Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed significantly elevated basal calcium concentrations in bipolar patient platelets and lymphocytes compared to control subjects."
    explanation: >-
      Direct measurement of the elevated basal calcium finding in 30 affective
      disorder patients versus 14 controls, the replicated peripheral-cell
      observation this node records.
  - reference: PMID:10418700
    reference_title: "Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "our data suggest that storage operated calcium channels may be the source of the elevated intracellular calcium in platelets and lymphocytes of bipolar patients"
    explanation: >-
      Locates the abnormality at store-operated calcium entry rather than at
      the plasma-membrane voltage-gated channels implicated by the CACNA1C
      genetics, so the two calcium findings are complementary rather than the
      same lesion measured twice.
  - reference: PMID:21167476
    reference_title: "The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These results demonstrate that, in patients with BPD, abnormal Bcl-2 gene expression in the AA variant contributes to dysfunctional Ca(2+) homeostasis through a specific ER inositol 1,4,5-trisphosphate receptor-dependent mechanism."
    explanation: >-
      Supplies a genotype-to-mechanism account for part of the calcium
      abnormality: reduced BCL2 expression in rs956572 AA carriers enhances
      IP3-receptor-dependent ER calcium release. Scope caveat -- 18 patient
      lymphoblast lines, a peripheral cell model, not neurons.
  - reference: PMID:21167476
    reference_title: "The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The aberrant behavior of AA cells was reversed by chronic lithium treatment and mimicked in variant GG by a Bcl-2 inhibitor."
    explanation: >-
      Pharmacological convergence in both directions -- lithium normalizes the
      genotype-associated calcium phenotype and a BCL2 inhibitor reproduces it
      in non-risk cells -- which is what ties this node to the treatment
      section rather than leaving it as an isolated biomarker.
  downstream:
  - target: Mitochondrial Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Proposed rather than demonstrated. A published model argues that raised
      cytosolic calcium in mania drives increased mitochondrial respiration and
      ATP production, with the euthymic and depressive phases showing the
      opposite. No study cited here measures calcium and mitochondrial
      respiration in the same subjects across a mood transition, so the edge is
      recorded at unknown-intermediate directness.
    intermediate_mechanisms:
    - Raised cytosolic calcium is proposed to stimulate oxidative
      phosphorylation, in part through modulation of the F1-FO elements of ATP
      synthase, alongside oxidative stress and pro-inflammatory cytokine
      signaling that are themselves higher in mania.
    evidence:
    - reference: PMID:28093238
      reference_title: "A model of the mitochondrial basis of bipolar disorder."
      supports: SUPPORT
      evidence_source: OTHER
      directness: INDIRECT
      snippet: "Levels of oxidative stress, pro-inflammatory cytokines and intracellular calcium ions are all higher in bipolar mania than in the euthymic and depressive phases of the illness."
      explanation: >-
        States the calcium-to-mitochondrial-respiration step this edge encodes.
        Graded OTHER and INDIRECT because the source is an explanatory model
        paper synthesizing prior literature, not a study that tested the
        proposed sequence.
- name: Neuronal Hyperexcitability
  biological_scale: CELLULAR
  description: >
    Patient-derived neurons show intrinsic hyperexcitability, offering a
    cellular endophenotype that sits between the ion-channel genetics and the
    circuit-level findings. iPSC-derived hippocampal dentate-gyrus-like
    granule neurons from bipolar patients fire action potentials hyperactively
    and carry mitochondrial abnormalities relative to control-derived neurons.
    The finding is also a treatment-response stratifier: lithium reverses the
    hyperexcitability only in neurons from donors who were themselves clinical
    lithium responders. Scope limits -- six manic bipolar I donors and four
    unaffected individuals, one differentiated neuron type, and no
    demonstration that hyperexcitability causes episode switching rather than
    marking trait vulnerability.
  cell_types:
  - preferred_term: iPSC-derived hippocampal dentate gyrus-like granule neuron
    term:
      id: CL:0001033
      label: hippocampal granule cell
  biological_processes:
  - preferred_term: Action Potential Firing
    term:
      id: GO:0001508
      label: action potential
    modifier: INCREASED
  - preferred_term: Regulation of Neuronal Membrane Potential
    term:
      id: GO:0042391
      label: regulation of membrane potential
    modifier: ABNORMAL
  evidence:
  - reference: PMID:26524527
    reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: "we have detected mitochondrial abnormalities in young neurons from patients with bipolar disorder by using mitochondrial assays; in addition, using both patch-clamp recording and somatic Ca(2+) imaging, we have observed hyperactive action-potential firing."
    explanation: >-
      The primary measurement behind this node: patch-clamp and calcium imaging
      in patient-derived dentate-gyrus-like neurons show hyperactive
      action-potential firing alongside mitochondrial abnormalities, in
      patient-derived human tissue rather than an animal model.
  - reference: PMID:26524527
    reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This hyperexcitability phenotype of young neurons in bipolar disorder was selectively reversed by lithium treatment only in neurons derived from patients who also responded to lithium treatment."
    explanation: >-
      The responder-selective rescue is what makes this node a candidate
      treatment-response stratifier rather than a generic cellular abnormality:
      the in-vitro correction tracks the donor's own clinical lithium response.
      It holds for the sampled lines and has not been shown to generalize
      across the heterogeneity of bipolar disorder.
- name: Mitochondrial Dysfunction
  description: >
    Impaired cellular energy metabolism and oxidative stress affect
    neuronal function. Mitochondrial abnormalities linked to mood
    dysregulation.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: NO_EVIDENCE
    snippet: "Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide."
    explanation: This review discusses the molecular mechanisms underlying psychiatric disorders including bipolar disorder, with focus on the DISC1/GSK3 complex which regulates mitochondrial and cellular functions.
  - reference: PMID:26524527
    reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Strikingly, we found that the expression of multiple mitochondria genes was significantly enhanced in the BD neurons"
    explanation: >-
      RNA-seq of patient-derived dentate-gyrus-like neurons finds coordinated
      upregulation of mitochondrial genes, the first direct measurement
      supporting this node in patient-derived human neurons rather than by
      inference from review literature.
  - reference: PMID:26524527
    reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Flow cytometry analysis revealed that BD neurons showed increased red/green ratios, indicative of enhanced mitochondrial function"
    explanation: >-
      Note the direction: membrane-potential assay in young patient-derived
      neurons shows *enhanced* mitochondrial function, not the deficit the node
      description implies. Curated as a qualification -- the abnormality is
      established, but this study argues against reading it uniformly as
      impaired energy metabolism, consistent with the phasic model in which
      respiration is raised in mania and lowered in euthymia and depression.
- name: Circadian Rhythm Disruption
  description: >
    Disrupted sleep-wake cycles and circadian gene expression
    contribute to mood instability. Sleep deprivation can trigger mania.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Circadian Rhythm
    term:
      id: GO:0007623
      label: circadian rhythm
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: NO_EVIDENCE
    snippet: "For more than 60 years, the mood stabilizer lithium has been used alone or in combination for the treatment of bipolar disorder, schizophrenia, depression, and other mental illnesses."
    explanation: This comprehensive review discusses lithium as the gold standard treatment for bipolar disorder, noting its mood-stabilizing effects through GSK3 inhibition which affects multiple cellular pathways including circadian regulation.
  - reference: PMID:23919927
    reference_title: "Glycogen synthase kinase-3β haploinsufficiency lengthens the circadian locomotor activity period in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "these data suggest that GSK3β acts as a critical intrinsic regulator of the circadian clock and plays an important role in regulating its period in response to lithium treatment"
    explanation: >-
      GSK3β haploinsufficiency lengthens circadian period in mice, mechanistically
      linking lithium's inhibition of GSK3β to its documented effects on circadian
      rhythm period and amplitude in bipolar disorder.
  - reference: PMID:20591414
    reference_title: "Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We found that knockdown of Clock, specifically in the VTA, results in hyperactivity and a reduction in anxiety-related behavior, which is similar to the phenotype of the ClockDelta19 mice."
    explanation: >-
      Region-restricted RNA-interference knockdown shows that disrupting a
      single core clock gene in one brain region is sufficient to produce
      mania-like behavior, which is the strongest causal support available for
      the circadian pillar of this model.
  - reference: PMID:20591414
    reference_title: "Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "However, VTA-specific knockdown also results in a substantial increase in depression-like behavior, creating an overall mixed manic state."
    explanation: >-
      The qualification the model needs, quoted from the same result. The
      manipulation does not produce cycling between separable manic and
      depressive states; the authors characterize the outcome as a single mixed
      state. So this is a mouse demonstration that clock disruption destabilizes
      mood-related behavior, not a demonstration of the episodic switching the
      canonical model is invoked to explain.
  downstream:
  - target: Monoamine Dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Clock-gene disruption raises dopaminergic output. Evidence is a targeted
      rodent perturbation; no human circadian variant has been shown to drive
      dopaminergic change in bipolar patients, so the edge is model-organism
      grounded rather than established in human disease.
    intermediate_mechanisms:
    - Loss of CLOCK function in ventral tegmental area dopaminergic neurons
      alters expression of ion channels and dopamine-related genes, increasing
      the firing activity of those neurons and so raising dopaminergic drive to
      forebrain reward circuits.
    evidence:
    - reference: PMID:20591414
      reference_title: "Knockdown of Clock in the ventral tegmental area through RNA interference results in a mixed state of mania and depression-like behavior."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "VTA dopaminergic neurons expressing the Clock short hairpin RNA have increased activity compared with control neurons"
      explanation: >-
        The electrophysiological measurement that grounds this specific edge:
        clock-gene knockdown increases dopaminergic neuron firing, the step
        connecting the circadian node to the monoaminergic node.
- name: Neuroplasticity Alterations
  description: >
    Reduced BDNF and altered synaptic plasticity in mood circuits.
    Lithium and other mood stabilizers enhance neuroplasticity.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  evidence:
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: SUPPORT
    snippet: "DISC1 binds directly to GSK3 and modulates many cellular functions by negatively inhibiting GSK3 activity."
    explanation: GSK3 inhibition by DISC1 and mood stabilizers like lithium is a key mechanism in bipolar disorder treatment, affecting synaptic plasticity and neuronal survival pathways.
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: SUPPORT
    snippet: "In the present review, we will focus on the emerging roles of TRAX and its interacting proteins (including DISC1 and GSK3β) in psychiatric disorders and the potential implications for developing therapeutic interventions."
    explanation: The TRAX/DISC1/GSK3β complex is implicated in psychiatric disorders including bipolar disorder and represents a therapeutic target for enhancing neuroplasticity.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 activity and also to induce signaling mediated by brain-derived neurotrophic factor."
    explanation: >-
      Lithium enhances neuroplasticity in part by inducing BDNF signaling and
      inhibiting GSK-3, directly complementing the reduced-BDNF pathophysiology
      captured in this node.
- name: Neuroinflammation
  description: >
    Elevated inflammatory markers during mood episodes. Microglial
    activation and cytokine abnormalities contribute to pathophysiology.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:33958577
    reference_title: "Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia."
    supports: NO_EVIDENCE
    snippet: "considering that schizophrenia is a multifactorial and highly polygenic disorder that shares many risk genes with other psychiatric illnesses including bipolar disorder, depression, intellectual disability and autism spectrum disorders, it is to be expected that these diseases may also share some of these same mechanisms"
    explanation: Microglial activation and inflammatory processes are shared pathophysiological mechanisms across psychiatric disorders including bipolar disorder, contributing to synaptic dysfunction.
- name: GSK-3β Signaling Dysregulation
  description: >
    Glycogen synthase kinase-3β (GSK-3β) is a constitutively active
    serine/threonine kinase that phosphorylates β-catenin, tau, and numerous
    circadian and pro-apoptotic substrates. Excess GSK-3β activity is implicated
    in bipolar mood instability, and GSK-3β is the principal molecular target
    through which lithium is thought to exert its mood-stabilizing and
    neuroprotective effects. Lithium inhibits GSK-3β both directly
    (Mg2+-competitive) and indirectly (via the Akt / β-arrestin-2 / PP2A axis),
    stabilizing β-catenin and mimicking canonical Wnt signaling.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Canonical Wnt Signaling
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:8710892
    reference_title: "A molecular mechanism for the effect of lithium on development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
    explanation: >-
      Klein and Melton identified GSK-3β as a direct molecular target of lithium
      in developmental model organisms — the foundational evidence for the GSK-3β
      hypothesis of lithium's action in bipolar disorder.
  - reference: PMID:8710892
    reference_title: "A molecular mechanism for the effect of lithium on development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Lithium potently inhibits GSK-3 beta activity (Ki = 2 mM), but is not a general inhibitor of other protein kinases."
    explanation: >-
      Lithium inhibits GSK-3β at therapeutically relevant concentrations with
      selectivity over other protein kinases, supporting GSK-3β as a specific target.
  - reference: PMID:8994831
    reference_title: "Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Li+ treatment of Drosophila S2 cells and rat PC12 cells induces accumulation of cytoplasmic Armadillo/beta-catenin, demonstrating that Li+ can mimic Wingless signalling in intact cells, consistent with its inhibition of GSK-3."
    explanation: >-
      In intact mammalian (PC12) and insect cells, lithium inhibition of GSK-3
      stabilizes β-catenin and reproduces canonical Wnt (Wingless) signaling,
      tying GSK-3β inhibition to a defined downstream pathway.
  downstream:
  - target: Circadian Rhythm Disruption
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - GSK-3β phosphorylates core clock proteins, so excess GSK-3β activity
      shortens/destabilizes circadian period and amplitude (lithium's GSK-3β
      inhibition lengthens period, per the GSK3β-haploinsufficiency model).
  - target: Neuroplasticity Alterations
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Excess GSK-3β activity suppresses BDNF/neurotrophic and β-catenin survival
      signaling, impairing synaptic plasticity in fronto-limbic mood circuits.
- name: Phosphoinositide Signaling Dysregulation
  description: >
    Overactivity of the phosphatidylinositol (PIP2 / IP3) second-messenger cycle
    is implicated in bipolar mood instability (the "inositol depletion
    hypothesis"). The cycle regenerates free myo-inositol through inositol
    monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase; lithium
    uncompetitively inhibits these Mg2+-dependent phosphatases, depleting free
    inositol and dampening the overactive signaling — a therapeutic target
    shared with valproate and carbamazepine. (The disease-state direction shown
    here is the overactive baseline; lithium's opposing, inhibitory action is
    captured on the Lithium treatment's target_mechanisms edge.)
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Inositol Phosphate Metabolism
    term:
      id: GO:0043647
      label: inositol phosphate metabolic process
    modifier: INCREASED
  - preferred_term: Phosphatidylinositol-Mediated Signaling
    term:
      id: GO:0048015
      label: phosphatidylinositol-mediated signaling
    modifier: INCREASED
  evidence:
  - reference: PMID:12015604
    reference_title: "A common mechanism of action for three mood-stabilizing drugs."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
    explanation: >-
      Williams et al. showed that lithium, valproate, and carbamazepine converge
      on inositol depletion — exogenous inositol rescues their shared cellular
      effect, direct evidence for the inositol-depletion mechanism.
  - reference: PMID:12015604
    reference_title: "A common mechanism of action for three mood-stabilizing drugs."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Berridge and colleagues suggested that inositol depletion may be the way that lithium works in bipolar affective disorder, but others have suggested that glycogen synthase kinase (GSK3) may be the relevant target."
    explanation: >-
      Frames the two leading molecular hypotheses of lithium action — inositol
      depletion versus GSK-3 inhibition — both of which are curated as distinct
      pathophysiology nodes in this entry.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "By inhibiting the activity of phosphoinositol phosphatases, it decreases levels of inositol 1,4,5-trisphosphate, a process recently identified as a novel mechanism for inducing autophagy."
    explanation: >-
      Lithium inhibition of inositol phosphatases lowers IP3 and links inositol
      depletion to autophagy induction, a downstream neuroprotective consequence.
phenotypes:
- name: Manic Episodes
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Elevated mood, decreased sleep, increased activity
  phenotype_term:
    preferred_term: Mania
    term:
      id: HP:0100754
      label: Mania
- name: Depressive Episodes
  category: Psychiatric
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:26388529
    reference_title: "Bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "onset is most commonly a depressive episode and looks similar to unipolar depression"
    explanation: Depressive episodes are the most common presenting mood state in bipolar disorder, frequently mimicking unipolar major depression.
- name: Sleep Disturbance
  category: Psychiatric
  frequency: VERY_FREQUENT
  notes: Decreased need for sleep in mania, insomnia or hypersomnia in depression
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
- name: Psychosis
  category: Psychiatric
  frequency: OCCASIONAL
  notes: Can occur in severe mania or depression
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
- name: Anxiety
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
- name: Cognitive Impairment
  category: Neurological
  frequency: FREQUENT
  notes: Executive function, attention deficits
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:23846857
    reference_title: "Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)."
    supports: SUPPORT
    snippet: "All proband groups showed lower psychosocial functioning than the relatives or comparison group. On average, schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."
    explanation: The B-SNIP study demonstrates that cognitive and psychosocial impairment is a consistent feature across psychotic disorders including bipolar disorder, though with varying severity.
biochemical:
- name: BDNF
  presence: Decreased
  context: Reduced in both manic and depressive episodes
- name: Cortisol
  presence: Elevated
  context: HPA axis dysregulation
- name: Inflammatory Markers
  presence: Elevated
  context: IL-6, TNF-alpha during episodes
genetic:
- name: CACNA1C
  gene_term:
    preferred_term: CACNA1C
    term:
      id: hgnc:1390
      label: CACNA1C
  association: Risk Factor
  notes: Calcium channel
  evidence:
  - reference: PMID:18711365
    reference_title: "Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder."
    supports: SUPPORT
    snippet: "We also found further support for the previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel; combined P = 7.0 x 10(-8), rs1006737)."
    explanation: Landmark GWAS study providing genome-wide significant evidence that CACNA1C is a susceptibility locus for bipolar disorder, implicating calcium channel dysfunction in disease pathogenesis.
  - reference: PMID:21057379
    reference_title: "Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes."
    supports: SUPPORT
    snippet: "The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
    explanation: Case-case GWAS analysis further confirms the critical role of calcium channel genes including CACNA1C in bipolar disorder susceptibility.
  - reference: PMID:25403839
    reference_title: "Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons."
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: "we performed electrophysiology and quantitative PCR experiments that demonstrated increased L-type VGCC current density as well as increased mRNA expression of CACNA1C in iNs homozygous for the risk genotype, compared with non-risk genotypes"
    explanation: >-
      Bridges the variant-to-function gap for the entry's flagship risk gene:
      induced human neurons from over 20 fibroblast lines show that the
      rs1006737 risk genotype raises CACNA1C transcript level and L-type
      calcium current density, fixing the direction of effect as gain of
      channel function. Scope caveat recorded by the authors themselves --
      the rs1006737 haplotype is transdiagnostic and the donors included
      unaffected individuals, so this establishes a genotype-to-channel
      phenotype rather than a bipolar-specific circuit mechanism.
  - reference: PMID:39370418
    reference_title: "Cacna1c deficiency in forebrain glutamatergic neurons alters behavior and hippocampal plasticity in female mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: INDIRECT
    snippet: "In the hippocampus, Cav1.2 inactivation enhanced presynaptic paired-pulse facilitation without altering postsynaptic LTP at CA3-CA1 synapses. In addition, CA1 pyramidal neurons of female CKO mice displayed a reduction in dendritic complexity and spine density."
    explanation: >-
      Cell-type-restricted Cav1.2 loss in forebrain glutamatergic neurons
      produces behavioral, synaptic, and dendritic changes, establishing that
      the channel is functionally required in exactly the neuron class this
      model implicates. Graded INDIRECT because the direction is opposite to
      the human risk allele: this is a loss-of-function knockout, whereas
      PMID:25403839 associates the risk genotype with increased CACNA1C
      expression and current. The phenotypes are also not bipolar-specific,
      so the study is gene-function evidence rather than directionally
      convergent validation of the human risk edge.
- name: ANK3
  gene_term:
    preferred_term: ANK3
    term:
      id: hgnc:494
      label: ANK3
  association: Risk Factor
  notes: Ankyrin-3
  evidence:
  - reference: PMID:18711365
    reference_title: "Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder."
    supports: SUPPORT
    snippet: "To identify susceptibility loci for bipolar disorder, we tested 1.8 million variants in 4,387 cases and 6,209 controls and identified a region of strong association (rs10994336, P = 9.1 x 10(-9)) in ANK3 (ankyrin G)."
    explanation: Genome-wide significant association of ANK3 with bipolar disorder in large-scale GWAS, establishing ankyrin G as a key susceptibility gene that may affect neuronal excitability and synaptic function.
- name: ODZ4
  association: Risk Factor
  evidence:
  - reference: PMID:21926972
    reference_title: "Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In particular, we support prior findings in CACNA1C, and now identify ODZ4 as associated with BD."
    explanation: Psychiatric GWAS Consortium large-scale GWAS established genome-wide-significant association of the teneurin gene ODZ4 (TENM4) with bipolar disorder.
- name: NCAN
  gene_term:
    preferred_term: NCAN
    term:
      id: hgnc:2465
      label: NCAN
  association: Risk Factor
  evidence:
  - reference: PMID:21353194
    reference_title: "Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with BD"
    explanation: GWAS with independent replication identified the extracellular-matrix glycoprotein gene NCAN (neurocan) as a genome-wide-significant bipolar disorder susceptibility locus.
- name: SETD1A
  gene_term:
    preferred_term: SETD1A
    term:
      id: hgnc:29010
      label: SETD1A
  association: Candidate risk factor (founder-population missense allele; nominal association, not yet replicated)
  relationship_type: SUSCEPTIBILITY
  notes: >-
    SETD1A encodes a histone H3K4 methyltransferase and is an established
    large-effect schizophrenia risk gene; its status as a bipolar-disorder risk
    gene is far weaker and rests, at present, on a single founder-population
    study. A missense allele enriched 55-fold in the Lancaster Old Order Amish
    (p.Pro596Leu, rs139187973) was associated with a 1.8-fold relative risk for
    bipolar disorder at nominal significance only (P = 0.027), in a
    non-peer-reviewed preprint. The allele-dose-dependent cognitive effect and
    the patient-derived iPSC phenotypes are the stronger part of that report;
    the diagnostic association itself is the weaker part, and is recorded here
    as a lead rather than an established locus. See the linked KNOWLEDGE_GAP
    discussion for what replication would require.
  variants:
  - name: SETD1A p.Pro596Leu (rs139187973)
    description: >-
      A missense substitution outside the catalytic SET domain, at 5.2% allele
      frequency in the Lancaster Old Order Amish versus 0.09% in gnomAD exomes.
      Patient-derived iPSCs homozygous for the allele show signatures of SETD1A
      hypofunction rather than a clean null, so the allele is best read as a
      hypomorph rather than as equivalent to the loss-of-function alleles that
      drive the schizophrenia association.
    type: missense variant
    functional_effects:
    - function: histone H3K4 methyltransferase activity
      description: >-
        Homozygous carrier iPSCs proliferate more slowly and are markedly more
        susceptible to hydroxyurea-induced DNA double-strand breaks; the
        proliferation deficit is rescued by overexpression of reference-sequence
        SETD1A, and neurite and senescence phenotypes are partially rescued by
        inhibiting the opposing H3K4 demethylase KDM5.
      type: loss-of-function
    evidence:
    - reference: PPR:PPR1277941
      reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Exome sequencing (n = 3,736) revealed a population-enriched SETD1A
        missense variant (P596L) in the Lancaster Old Order Amish founder
        population, presenting a unique opportunity to elucidate
        variant-specific, multi-scale mechanisms.
      explanation: >-
        Establishes the founder-population enrichment that makes this specific
        allele tractable, and the reason it is not informative about
        bipolar-disorder risk in the general population.
    - reference: PPR:PPR1277941
      reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Induced pluripotent stem cells (iPSCs) from homozygous carriers
        exhibited signatures of SETD1A hypofunction, including reduced
        proliferation and heightened susceptibility to replication stress and
        DNA double-strand breaks.
      explanation: >-
        Sources the hypomorph reading of the allele - patient-derived cells show
        reduced SETD1A function with genome-instability consequences rather than
        a null phenotype.
  evidence:
  - reference: PPR:PPR1277941
    reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was associated with a 1.8-fold relative risk for BD in our sample (P = 0.027; Fig. 1A)."
    explanation: >-
      The primary bipolar-disorder association, quoted with its effect size and
      p-value rather than from the abstract. The effect is nominal (P = 0.027,
      uncorrected), confined to a single founder population, and reported in a
      non-peer-reviewed preprint, so this is recorded as a lead rather than an
      established locus - see the linked knowledge gap for what replication
      would require.
  - reference: PPR:PPR1277941
    reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "homozygotes performing worse than heterozygotes, especially on the Verbal Memory subtest."
    explanation: >-
      An allele-dose-dependent quantitative phenotype in adult carriers, which
      is a stronger genetic argument than the diagnostic association itself
      because it does not depend on case ascertainment.
  - reference: PMID:26974950
    reference_title: "Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Together, our observations indicate that LoF variants in SETD1A cause a range of neurodevelopmental disorders, including schizophrenia."
    explanation: >-
      Peer-reviewed context for the gene, not for the bipolar association: SETD1A
      disruption already spans a range of neurodevelopmental diagnoses, which is
      the prior that makes a mood-disorder association plausible enough to
      record. It does not itself implicate SETD1A in bipolar disorder.
- name: ITIH3
  gene_term:
    preferred_term: ITIH3
    term:
      id: hgnc:6168
      label: ITIH3
  association: Risk Factor
  relationship_type: SUSCEPTIBILITY
  notes: >-
    ITIH3 lies in the extended 3p21.1 psychiatric risk region (GRCh38
    chr3:52.79-52.81 Mb), immediately adjacent to ITIH1 and ITIH4 and within the
    same long-range LD block as GNL3, NEK4, GLT8D1, SFMBT1 and NISCH. Scope
    caveat: the index SNPs reported by the largest bipolar disorder GWAS are inside this
    region but not inside ITIH3 itself (rs2336147 is ~185 kb proximal to the ITIH cluster), so this
    entry records a locus-level susceptibility signal, not a demonstrated ITIH3
    coding or regulatory effect. ITIH3/ITIH4 were specifically prioritized as the
    shared bipolar-disorder/OCD pleiotropic signal by a 2026 cross-trait conjFDR
    plus SMR/colocalization analysis, which remains a non-peer-reviewed preprint;
    the effector gene at 3p21.1 is still contested (see the attached knowledge
    gap). ITIH heavy chains covalently cross-link hyaluronan in the
    extracellular matrix, which would place this locus in the same
    ECM-remodelling theme as the established bipolar NCAN (neurocan) locus.
  evidence:
  - reference: PMID:34002096
    reference_title: "Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "9c 3 52626443 rs2336147 3.6 × 10−13 1.070 0.009 T/C 0.498 ITIH1 (PGC2) SCZ, CDG"
    explanation: >-
      Table 1 row from the PGC bipolar disorder GWAS (41,917 cases): locus 9,
      index SNP rs2336147 at chr3:52,626,443 (GRCh37; 3p21.1), P = 3.6 x 10^-13,
      OR 1.070, named by the authors for ITIH1 and previously reported for
      schizophrenia and by the Cross-Disorder Group. This is the peer-reviewed
      genome-wide-significant bipolar association at the ITIH-cluster locus; the
      index SNP itself sits proximal to the ITIH genes rather than within them.
  - reference: PPR:PPR1294131
    reference_title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "ConjFDR analysis revealed 2,143 pleiotropic SNPs jointly associated with BIP and OCD, with convergent signals at the ITIH3/ITIH4 locus."
    explanation: >-
      Cross-trait conjunctional-FDR analysis of bipolar disorder and OCD GWAS
      summary statistics converges on the ITIH3/ITIH4 locus. PARTIAL because
      this is a non-peer-reviewed preprint and a summary-statistics analysis: it
      prioritizes ITIH3/ITIH4 among the genes at 3p21.1 but does not
      experimentally establish either gene as the effector.
- name: AKAP11
  association: Risk Factor
  relationship_type: RISK_FACTOR
  notes: >-
    The one rare-variant risk gene curated for this entry, and the only one
    reaching exome-wide significance in bipolar disorder to date. Ultra-rare
    protein-truncating variants in AKAP11 are enriched in bipolar cases in the
    BipEx collaboration, but the headline gene-level result is reached only
    after meta-analysis with the schizophrenia SCHEMA exome data, so the risk
    is shared with schizophrenia rather than bipolar-specific. AKAP-11 is a
    PKA-anchoring scaffold that binds GSK3B, which is why the gene is read as
    rare-variant convergence on the pathway lithium is thought to act through;
    that inference rests on a protein-protein interaction, not on any
    demonstration that the truncating variants act via GSK3B or that GSK3B
    inhibition is lithium's necessary therapeutic mechanism. The same study
    found that common-variant GWAS loci are not enriched for ultra-rare
    truncating variants, so common and rare risk in bipolar disorder are at
    least partly distinct in their gene sets.
  evidence:
  - reference: PMID:35410376
    reference_title: "Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combining gene-level results with SCHEMA, AKAP11 emerges as a definitive risk gene"
    explanation: >-
      Whole-exome sequencing of 13,933 bipolar cases and 14,422 controls
      establishes AKAP11 as a bipolar risk gene. The qualification is in the
      sentence itself: the definitive gene-level result requires combining
      BipEx with the schizophrenia SCHEMA analysis, so this is a cross-disorder
      rather than bipolar-specific finding.
  - reference: PMID:35410376
    reference_title: "Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "At the protein level, AKAP-11 interacts with GSK3B, the hypothesized target of lithium, a primary treatment for BD."
    explanation: >-
      The basis for reading AKAP11 as independent rare-variant convergence on
      the GSK-3 beta pillar of this model. Graded INDIRECT because the link is
      a protein-protein interaction reported by the same paper, not a
      demonstration that AKAP11 truncating variants change GSK3B activity in
      patients.
  - reference: PMID:35410376
    reference_title: "Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genes implicated from genome-wide association studies (GWASs) of BD, however, are not significantly enriched for ultra-rare PTVs."
    explanation: >-
      Records that the common-variant loci curated above (CACNA1C, ANK3, ODZ4,
      NCAN, the 3p21.1 region) are not the genes carrying the rare truncating
      burden, so the polygenic common-variant architecture and the rare-variant
      architecture are at least partly separate rather than two readouts of one
      gene set.
environmental:
- name: Childhood Trauma
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Increases risk
  evidence:
  - reference: PMID:33364762
    reference_title: "The Impact of Childhood Trauma on Developing Bipolar Disorder: Current Understanding and Ensuring Continued Progress."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals with BD are 2.63 times more likely to report CT compared to healthy individuals"
    explanation: Review quantifies childhood trauma as a risk factor for bipolar disorder, with individuals with BD reporting childhood trauma at 2.63 times the rate of healthy individuals.
- name: Sleep Deprivation
  exposure_term:
    preferred_term: sleep deprivation
    term:
      id: XCO:0001069
      label: sleep restriction
  notes: Can trigger manic episodes
  evidence:
  - reference: PMID:10482346
    reference_title: "Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we observed a 4.85% switch rate into mania and a 5.83% switch rate into hypomania"
    explanation: Clinical trial of therapeutic sleep deprivation in 206 bipolar depressed patients measured the switch into mania (4.85%) and hypomania (5.83%), quantifying sleep loss as a trigger of manic episodes.
- name: Substance Use
  notes: Comorbid and can trigger episodes
  evidence:
  - reference: PMID:34833474
    reference_title: "Bipolar Disorder and Comorbid Use of Illicit Substances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes"
    explanation: "PARTIAL: this supports the comorbidity half of the annotation and an effect on clinical course, but not the episode-triggering half. The same review notes it is still unclear why bipolar patients are at higher risk of addictive disorders, so the direction of that relationship is not settled."
  - reference: PMID:27476137
    reference_title: "Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The SUDs with the highest prevalence in BD were alcohol use (42%) followed by cannabis use (20%) and other illicit drug use (17%)"
    explanation: Systematic review and meta-analysis quantifies the high prevalence of comorbid substance use disorders in bipolar disorder.
- name: Stress
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Life events can precipitate episodes
  evidence:
  - reference: PMID:24751308
    reference_title: "Stressful life events in bipolar I and II disorder: cause or consequence of mood symptoms?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Negative life events were significantly associated with both subsequent severity of mania and depressive symptoms and functional impairment"
    explanation: "Prospective study of 173 bipolar outpatients assessed quarterly for two years. PARTIAL because the same study found the reverse direction as well -- depressive symptoms preceded negative life events, and manic symptoms preceded positive ones -- so its own title asks whether life events are cause or consequence, and its authors state the design cannot settle that."
  - reference: PMID:36940629
    reference_title: "Triggers for acute mood episodes in bipolar disorder: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "possible triggers including fasting, decreased sleep and stressful life events"
    explanation: Systematic review of triggers for acute mood episodes in bipolar disorder identifies stressful life events among triggers for depressive relapse.
treatments:
- name: Lithium
  description: First-line mood stabilizer, effective for mania and suicide prevention.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lithium carbonate
      term:
        id: CHEBI:6504
        label: lithium carbonate
  target_mechanisms:
  - target: GSK-3β Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly
      (via Akt / β-arrestin-2 / PP2A), stabilizing β-catenin and mimicking
      canonical Wnt signaling — the principal proposed molecular basis of its
      mood-stabilizing effect.
    evidence:
    - reference: PMID:8710892
      reference_title: "A molecular mechanism for the effect of lithium on development."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
      explanation: Direct evidence that lithium acts by inhibiting GSK-3β.
  - target: Phosphoinositide Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Lithium uncompetitively inhibits inositol monophosphatase and related
      phosphatases, depleting free inositol and dampening PIP2 / IP3 signaling.
    evidence:
    - reference: PMID:12015604
      reference_title: "A common mechanism of action for three mood-stabilizing drugs."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
      explanation: Inositol rescue implicates inositol depletion as a mechanism of lithium action.
  - target: Circadian Rhythm Disruption
    treatment_effect: MODULATES
    description: >-
      Through GSK-3β inhibition lithium lengthens circadian period and stabilizes
      clock-gene rhythm amplitude, addressing circadian instability in bipolar disorder.
  - target: Neuroplasticity Alterations
    treatment_effect: MODULATES
    description: >-
      Lithium induces BDNF signaling and upregulates neurotrophic/neuroprotective
      pathways, enhancing synaptic plasticity in fronto-limbic mood circuits.
    evidence:
    - reference: PMID:41672966
      reference_title: "Lithium effects in the frontolimbic circuitry: a systematic review of neuroimaging findings in bipolar disorder."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: "Across modalities, lithium treatment was most consistently associated with larger volumes in the hippocampus, amygdala, anterior cingulate cortex (ACC), and prefrontal cortex (PFC), and with higher white-matter integrity within frontolimbic circuitry."
      explanation: >-
        Locates lithium's structural association in exactly the fronto-limbic
        regions this model names, at the circuit level rather than the
        molecular level. Graded INDIRECT deliberately: a volume association is
        an inference step away from the plasticity mechanism this edge asserts.
    - reference: PMID:41672966
      reference_title: "Lithium effects in the frontolimbic circuitry: a systematic review of neuroimaging findings in bipolar disorder."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overall risk of bias was substantial, yielding low-to-moderate certainty of evidence."
      explanation: >-
        The review's own certainty rating, curated alongside its headline result
        so the edge is not read as established causation. 78 of the 115 included
        studies were cross-sectional and only six were randomized, so the design
        base cannot separate a protective drug effect from confounding by who
        stays on lithium.
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"
    explanation: Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition.
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."
    explanation: Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "By inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, for instance, it suppresses the calcium-dependent activation of pro-apoptotic signaling pathways."
    explanation: >-
      Beyond GSK-3β and inositol depletion, lithium contributes to neuronal
      calcium homeostasis by limiting NMDA-receptor calcium influx and downstream
      pro-apoptotic signaling.
  - reference: PMID:38395906
    reference_title: "Lithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: a multi-omics replication study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway."
    explanation: >-
      Substantiates the pharmacogenomic qualification asserted in this entry's
      mechanistic-hypothesis notes. In 2,039 ConLiGen patients, the genetic
      signal for who responds to lithium falls in focal-adhesion and PI3K-Akt
      networks. Read precisely: the reported negative is for the ECM pathway,
      and the study did not test GSK3B or inositol pathways head to head, so it
      shows where the inter-individual response signal is rather than refuting
      the GSK-3β account of lithium's action.
  - reference: PMID:16179524
    reference_title: "The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials."
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: INDIRECT
    snippet: "The neuroprotective mechanisms involve inactivation of NMDA receptors through inhibition of NR2B tyrosine phosphorylation, activation of cell survival factors such as the PI 3-kinase/Akt signaling pathway, and induction of neurotrophic/neuroprotective proteins, including brain-derived neurotrophic factor, heat-shock protein (HSP), and Bcl-2."
    explanation: >-
      Provides the reconciliation between the two previous items: PI3K-Akt is
      itself part of lithium's neuroprotective signaling, and Akt phosphorylates
      and inactivates GSK-3β, so a PI3K-Akt response signal is compatible with a
      GSK-3β endpoint rather than being an alternative to it. Graded INDIRECT
      because this is rat primary neuronal culture work reviewed in a
      neuroprotection context, and the cascade reconciliation was not tested in
      the ConLiGen response cohort.
- name: Valproate
  description: Mood stabilizer, effective for mania.
  evidence:
  - reference: PMID:11473107
    reference_title: "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Valproic acid is widely used to treat epilepsy and bipolar disorder"
    explanation: Establishes valproate as a mood stabilizer used in bipolar disorder and identifies histone deacetylase inhibition as a molecular mechanism of action.
- name: Lamotrigine
  description: Mood stabilizer, more effective for depression prevention.
- name: Atypical Antipsychotics
  description: Quetiapine, olanzapine, aripiprazole for mania and maintenance.
- name: Antidepressants
  description: Used cautiously with mood stabilizer to prevent switch to mania.
- name: Psychotherapy
  description: >-
    CBT, interpersonal therapy, psychoeducation. Interpersonal and social
    rhythm therapy (IPSRT) is the arm that bears on this entry's circadian
    mechanism: it adds an explicit social-rhythm regulation component to
    interpersonal psychotherapy, and is the closest thing to a clinical test of
    whether stabilizing daily rhythms alters the course of bipolar disorder.
  target_mechanisms:
  - target: Circadian Rhythm Disruption
    treatment_effect: MODULATES
    description: >-
      IPSRT regularizes sleep and social routines, and greater achieved
      regularity during acute treatment tracks lower recurrence in maintenance.
      This is an association within a randomized trial rather than a
      demonstrated causal pathway: IPSRT is multicomponent, so the benefit
      cannot be attributed to the circadian component alone, and the
      social-rhythm analysis is mediational rather than a direct circadian
      perturbation.
    evidence:
    - reference: PMID:16143731
      reference_title: "Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: "Ability to increase regularity of social rhythms during acute treatment was associated with reduced likelihood of recurrence during the maintenance phase (P = .05)."
      explanation: >-
        The specific result linking rhythm regularity to clinical course, and so
        the only clinical evidence in this entry bearing on the circadian node
        as a modifiable target. Graded INDIRECT because it is an
        association between an achieved process measure and outcome, not a
        randomized manipulation of circadian timing.
  evidence:
  - reference: PMID:16143731
    reference_title: "Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "participants assigned to IPSRT in the acute treatment phase survived longer without a new affective episode (P = .01), irrespective of maintenance treatment assignment"
    explanation: >-
      Randomized trial in 175 acutely ill bipolar I patients showing that acute
      phase IPSRT lengthened time to a new episode over two years of
      maintenance. Note the scope: patients entered acutely ill rather than
      euthymic, so this is not the prevention-from-euthymia trial the entry's
      chronotherapy gap refers to.
  - reference: PMID:16143731
    reference_title: "Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed no difference between the treatment strategies in time to stabilization."
    explanation: >-
      Curated alongside the positive result to keep the claim bounded: IPSRT did
      not speed acute stabilization, and its benefit in this trial was confined
      to prophylaxis against later episodes.
  - reference: PMID:26388529
    reference_title: "Bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the evolving pharmacological and psychological strategies in bipolar disorder is of utmost importance"
    explanation: This clinical review emphasizes psychological (psychotherapeutic) strategies alongside pharmacotherapy as core to bipolar disorder management.
- name: ECT
  description: For severe or treatment-resistant episodes.
experimental_models:
- name: Bipolar patient iPSC-derived hippocampal dentate gyrus-like neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  description: >-
    Hippocampal dentate gyrus granule cell-like neurons differentiated from
    induced pluripotent stem cells of six patients with bipolar I disorder and
    four unaffected individuals. Three of the patients responded to lithium
    in a clinical trial and three did not. This is the only patient-derived
    model in this entry. The neurons were studied at three weeks of
    differentiation, with and without one week of 1 mM lithium chloride.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: iPSC-derived hippocampal dentate gyrus-like granule neuron
    term:
      id: CL:0001033
      label: hippocampal granule cell
  conditions:
  - Bipolar I disorder, compared with unaffected individuals
  - Lithium chloride at 1 mM for one week, in neurons from clinical lithium responders and non-responders
  cell_source: >-
    Induced pluripotent stem cells reprogrammed from skin fibroblasts of six
    patients with bipolar I disorder and four unaffected individuals, two
    clones per person. Patient-derived.
  publication: PMID:26524527
  modeled_mechanisms:
  - target: Neuronal Hyperexcitability
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Neurons from patients fire action potentials more readily than neurons
      from unaffected individuals. Lithium reverses the difference only in
      neurons from patients who responded to lithium clinically. This node was
      curated from this study.
    limitations: >-
      Six patients, all white men with bipolar I disorder recruited from
      lithium monotherapy trials, and one neuron type. The hyperexcitability
      was seen in three-week-old neurons and reversed as the neurons aged. No
      experiment shows that it causes mood episodes. Fidelity is MODERATE
      because the cells are patient-derived and human, but the finding has
      not been matched to a measurement in patients' brains.
    divergences:
    - divergence_type: POPULATION_MISMATCH
      materiality: QUALIFYING
      description: >-
        The six donors are white men with manic bipolar I disorder from
        lithium monotherapy trials. The entry covers bipolar disorder of all
        types, in all patients.
      evidence:
      - reference: PMID:26524527
        reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: "We collected and reprogrammed fibroblasts of six patients with manic type I bipolar disorder (BD) and four unaffected individuals"
        explanation: States the number and diagnosis of the donors.
    - divergence_type: TEMPORAL_SCOPE
      materiality: QUALIFYING
      description: >-
        The readout is from neurons three weeks into differentiation. The
        authors report that the hyperexcitability reverses in older neurons,
        so the finding describes young neurons in culture and not a stable
        state.
      evidence:
      - reference: PMID:26524527
        reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: "we observed that this hyperexcitability would reverse when the diseased neurons became old"
        explanation: Reports the loss of the phenotype in older neurons.
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        The culture is mostly one neuron type. Other hippocampal cell types,
        long-range inputs and mood circuits are absent, so the model shows a
        cell-intrinsic property and cannot show its effect on circuit
        activity.
    readouts:
    - name: Action-potential firing (patch-clamp recording and calcium imaging)
      target: Neuronal Hyperexcitability
      direction: INCREASED
      biological_processes:
      - preferred_term: Action Potential Firing
        term:
          id: GO:0001508
          label: action potential
      interpretation: >-
        Higher in neurons from patients than in neurons from unaffected
        individuals.
      evidence:
      - reference: PMID:26524527
        reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: "using both patch-clamp recording and somatic Ca(2+) imaging, we have observed hyperactive action-potential firing"
        explanation: The primary electrophysiology and imaging result.
    - name: Action-potential firing after lithium, in neurons from clinical lithium responders
      target: Neuronal Hyperexcitability
      direction: RESTORED
      biological_processes:
      - preferred_term: Action Potential Firing
        term:
          id: GO:0001508
          label: action potential
      interpretation: >-
        Lithium lowered firing toward the control level in neurons from
        responders and had no clear effect in neurons from non-responders.
      evidence:
      - reference: PMID:26524527
        reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: "This hyperexcitability phenotype of young neurons in bipolar disorder was selectively reversed by lithium treatment only in neurons derived from patients who also responded to lithium treatment."
        explanation: Reports the reversal and that it was limited to responders' neurons.
    evidence:
    - reference: PMID:26524527
      reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: "hyperexcitability is one early endophenotype of bipolar disorder"
      explanation: >-
        The authors' conclusion that the phenotype seen in patient-derived
        neurons belongs to the disorder.
  - target: Mitochondrial Dysfunction
    relationship: MEASURES
    fidelity: UNKNOWN
    model_scale: CELLULAR
    description: >-
      The same neurons show mitochondrial differences from control neurons:
      higher expression of mitochondrial genes and a higher mitochondrial
      membrane potential.
    limitations: >-
      The direction is the opposite of the impairment this node describes.
      Young patient-derived neurons show enhanced mitochondrial function, so
      the model supports a mitochondrial abnormality and does not support
      reading it as an energy deficit. The same donor and cell-type limits
      apply as for the hyperexcitability link.
    readouts:
    - name: Mitochondrial membrane potential (flow cytometry, red/green ratio)
      target: Mitochondrial Dysfunction
      direction: INCREASED
      interpretation: >-
        Higher in neurons from patients than in control neurons, which the
        authors read as enhanced mitochondrial function.
      evidence:
      - reference: PMID:26524527
        reference_title: "Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder."
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: "Flow cytometry analysis revealed that BD neurons showed increased red/green ratios, indicative of enhanced mitochondrial function"
        explanation: The membrane-potential measurement and its direction.
diagnosis:
- name: Mood Disorder Questionnaire screening
  description: >-
    The Mood Disorder Questionnaire (MDQ) is a brief self-report screening
    instrument for bipolar spectrum disorder. A positive screen identifies
    patients for diagnostic interview; it does not establish the diagnosis.
    Its panel code identifies the instrument and its total-score code carries
    the screening threshold.
  diagnosis_term:
    preferred_term: bipolar disorder screening
    term:
      id: NCIT:C15419
      label: Disease Screening
  measurements:
  - preferred_term: MDQ
    term:
      id: LOINC:85102-2
      label: Mood Disorder Questionnaire [MDQ]
  reference_ranges:
  - loinc_term:
      id: LOINC:84773-1
      label: Total score [MDQ]
    unit: '{score}'
    population: >-
      198 patients attending five outpatient clinics that primarily treat mood
      disorders, against the bipolar module of the Structured Clinical
      Interview for DSM-IV (Hirschfeld et al. 2000)
    notes: >-
      The source states "A Mood Disorder Questionnaire screening score of 7 or
      more items yielded good sensitivity (0.73) and very good specificity
      (0.90)", so 7 is the inclusive lower bound of the upper band. The band
      records that item-count threshold exactly as the abstract states it and
      nothing more; any further conditions the instrument's scoring
      instructions attach to a positive screen are not in the cited abstract
      and are not recorded here. In a general-population validation led by the
      same first author, the MDQ showed sensitivity 0.281 and specificity 0.972
      (PMID:12505821, whose abstract does not state the threshold used), so the
      instrument's operating characteristics depend on setting.
    interpretation_bands:
    - name: Below the screening threshold
      lower_bound: 0
      upper_bound: 7
      unit: '{score}'
      abnormal_flag: NORMAL
    - name: Screening threshold met (7 or more items)
      lower_bound: 7
      unit: '{score}'
      abnormal_flag: HIGH
    evidence:
    - reference: PMID:11058490
      reference_title: "Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A Mood Disorder Questionnaire screening score of 7 or more items
        yielded good sensitivity (0.73) and very good specificity (0.90).
      explanation: >-
        States the screening threshold recorded as the lower bound of the
        upper band.
  notes: >-
    Copyright 2002 © Dr. Robert Hirschfeld. Used with permission.
  evidence:
  - reference: PMID:11058490
    reference_title: "Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Mood Disorder Questionnaire is a useful screening instrument for
      bipolar spectrum disorder in a psychiatric outpatient population.
    explanation: >-
      The validation study's conclusion supporting the MDQ as a bipolar
      spectrum screening instrument in psychiatric outpatients.
  - reference: PMID:12505821
    reference_title: "Validity of the mood disorder questionnaire: a general population study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The operating characteristics of the Mood Disorder Questionnaire in the
      general population differ substantially from its characteristics in
      outpatient psychiatric settings.
    explanation: >-
      A general-population validation showing that the instrument's accuracy
      differs by setting, which qualifies how a positive screen is read.
discussions:
- discussion_id: gap_bipolar_episodic_switching_trigger
  prompt: >-
    What determines the switch between manic and depressive states in bipolar
    disorder, and in what temporal order do the components of the canonical
    model change around a switch - does calcium dysregulation precede circadian
    disruption, the reverse, or do both follow an upstream trigger not yet in
    the model?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model
  - pathophysiology#Intracellular Calcium Dysregulation
  - pathophysiology#Circadian Rhythm Disruption
  rationale: >-
    Episodic cycling is the defining clinical feature of bipolar disorder and
    is the part of the canonical model with the weakest evidential support.
    Every pillar curated in this entry is a vulnerability or trait finding
    rather than a transition mechanism, and this shows up consistently in the
    primary sources rather than only in the abstract. The replicated
    peripheral-cell calcium abnormality showed little correlation with
    mood-rating severity in the series that established it (PMID:10418700), so
    the most reproducible cellular finding in the field is not obviously
    state-coupled. The patient-derived neuron work characterizes
    hyperexcitability as an early endophenotype in young neurons
    (PMID:26524527), not as a state marker. The strongest causal circadian
    manipulation available produces a single mixed state rather than
    alternation between separable poles (PMID:20591414). The phasic
    mitochondrial account that does address state (PMID:28093238) is explicitly
    a proposed explanatory model synthesizing cross-sectional comparisons, not
    a study of transition dynamics: comparing manic to euthymic subjects
    establishes that states differ, which is a different claim from
    establishing what moves a patient between them. This gap is the substantive
    content of the PARTIALLY_SUPPORTED verdict returned by the 2026
    OpenScientist assessment of this hypothesis - the framework organizes
    vulnerability well and does not currently explain episodicity - and it is
    why the entry retains CANONICAL status for the vulnerability model without
    asserting a switching mechanism.
  proposed_experiments:
  - experiment_id: exp_bipolar_peri_switch_longitudinal_multiomics
    name: Densely sampled longitudinal multi-omics through a mood switch
    description: >-
      Follow rapid-cycling bipolar patients through spontaneous mood
      transitions with dense temporal sampling - weekly peripheral blood for
      intracellular calcium, transcriptomics, cytokines and cortisol, continuous
      actigraphy and sleep timing for circadian phase, and periodic imaging -
      so that the order in which calcium, circadian and inflammatory measures
      change relative to clinical switch can be established within individuals.
      Within-subject design is essential: cross-sectional comparison of manic
      and euthymic groups cannot recover temporal ordering.
    experiment_type:
      preferred_term: longitudinal within-subject observational study
    would_support:
    - pathophysiology#Intracellular Calcium Dysregulation
    - pathophysiology#Circadian Rhythm Disruption
    - mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model
    would_refute:
    - mechanistic_hypotheses#canonical_polygenic_synaptic_circadian_dysregulation_model
    supporting_outcome:
    - >-
      Calcium or circadian measures change reproducibly in a consistent
      direction and in a consistent order in the days preceding clinical
      switch, across multiple patients and multiple switches, which would
      promote the corresponding node from a trait association to a step in the
      switching mechanism.
    - >-
      Circadian phase shift consistently precedes the calcium change, which
      would order the two pillars and identify circadian destabilization as the
      proximal trigger rather than a parallel correlate.
    refuting_outcome:
    - >-
      Calcium and circadian measures remain flat across switches, or change
      only after clinical state has already changed, which would establish them
      as trait vulnerability markers and consequences respectively and force
      the switching trigger to be sought outside the components this model
      names.
    decision_criterion: >-
      The model gains a switching mechanism only if a measured change in a
      curated node reliably precedes clinical switch within individuals. Change
      that follows the switch, or that does not replicate across patients,
      leaves the gap open regardless of effect size.
  evidence:
  - reference: PMID:10418700
    reference_title: "Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also found little correlation between calcium measures and the severity of mood rating."
    explanation: >-
      The null result that opens this gap. The same study that established the
      elevated-calcium finding found it did not track mood severity, so the
      field's most replicated cellular abnormality is not demonstrably
      state-coupled.
  - reference: PMID:28093238
    reference_title: "A model of the mitochondrial basis of bipolar disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "there is accumulating evidence indicating increased mitochondrial respiration and ATP production in bipolar mania which contrasts with decreased mitochondrial function in patients in the euthymic or depressive phase of the illness"
    explanation: >-
      States the phasic proposal that is currently the field's best answer to
      the switching question, and shows what it rests on: cross-sectional
      contrasts between mood states. Establishing that states differ is not the
      same as establishing what causes transition between them, which is why
      the gap remains open.
- discussion_id: gap_bipolar_calcium_channel_psychiatric_cardiovascular_pleiotropy
  prompt: >-
    Do the calcium-channel susceptibility loci shared between bipolar disorder
    and cardiovascular disease (the established CACNA1C locus plus the
    pleiotropic genes TPCN1, CACNA2D2, CACNA1D, and ATP2B1) reflect a single
    causal calcium-signaling axis acting in both brain and cardiovascular
    tissue, and what is the direction of causation - does psychiatric-risk
    calcium-channel genotype drive cardiac electrophysiological change (e.g.,
    QTc prolongation), or the converse?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#CACNA1C
  rationale: >-
    A genome-wide pairwise pleiotropy study in East Asians (Zhu et al., 2026;
    PMID:42436150) found shared genetic architecture across psychiatric and
    cardiovascular disease pairs converging on voltage-dependent calcium-channel
    activity, with novel pleiotropic genes (TPCN1, CACNA2D2, CACNA1D, ATP2B1)
    enriched in the calcium-signaling pathway alongside the established
    bipolar/schizophrenia locus CACNA1C. A calcium-pathway polygenic risk score
    was associated with prolonged QTc, and drug-target analysis implicated
    calcium-channel blockers and peripheral vasodilators in elevated
    schizophrenia risk while diuretics reduced risk across schizophrenia,
    bipolar disorder, and major depressive disorder. The unresolved gaps are
    (1) whether the same calcium-channel variants are the primary driver in
    brain versus a secondary consequence in cardiovascular tissue
    (tissue-specific direction of effect), (2) the causal direction of the
    calcium-genotype to QTc association, and (3) the mechanistic basis for the
    apparent antagonistic pleiotropy in treatment response - why L-type
    calcium-channel modulation may be relevant to mood episodes yet
    calcium-channel blockade associates with increased psychiatric risk at the
    population-genetic level. Resolving this bears directly on the safety of
    calcium-channel blockers in patients with concurrent bipolar disorder and
    cardiovascular disease. This is a cross-disease gap shared with the
    Schizophrenia, Major Depressive Disorder, and Coronary Artery Disease
    entries (dismech issue #6382).
  proposed_experiments:
  - experiment_id: exp_bipolar_calcium_pleiotropy_tissue_mr
    name: Tissue-stratified Mendelian randomization of the calcium axis
    description: >-
      Use brain- and cardiovascular-tissue eQTLs to instrument the pleiotropic
      calcium-channel genes (CACNA1C, CACNA1D, CACNA2D2, ATP2B1, TPCN1) in
      bidirectional Mendelian randomization against bipolar disorder,
      schizophrenia, QTc interval, and coronary artery disease, across
      independent and cross-ancestry cohorts.
    experiment_type:
      preferred_term: Mendelian randomization study
    decision_criterion: >-
      A shared causal calcium-signaling axis would be supported if the same
      tissue-specific calcium-channel instruments showed concordant, directional
      effects on both psychiatric and cardiovascular endpoints; discordant or
      tissue-limited effects would instead argue for parallel, tissue-restricted
      mechanisms.
  evidence:
  - reference: PMID:42436150
    reference_title: "Calcium signaling pathway implicates a shared genetic basis between psychiatric and cardiovascular diseases."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Among the novel pleiotropic genes, TPCN1, CACNA2D2, CACNA1D, and ATP2B1 are involved in voltage-dependent calcium channel activity, regulation of calcium influx, enriched in calcium-related pathway."
    explanation: >-
      Genome-wide pairwise pleiotropy analysis identifies shared
      calcium-channel genes across psychiatric and cardiovascular disease,
      motivating the shared-axis question.
  - reference: PMID:42436150
    reference_title: "Calcium signaling pathway implicates a shared genetic basis between psychiatric and cardiovascular diseases."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Our findings implicated that calcium-channel blockers and peripheral vasodilators elevated SCZ risk, diuretics reduced the risks of SCZ, BIP, and MDD."
    explanation: >-
      Drug-target analysis underpinning the antagonistic-pleiotropy
      treatment-response gap for calcium-channel modulation.
- discussion_id: gap_bipolar_setd1a_p596l_replication
  prompt: >-
    Does the SETD1A p.Pro596Leu association with bipolar disorder replicate
    outside the Lancaster Old Order Amish founder population, and is SETD1A a
    bipolar-disorder risk gene in its own right or only a schizophrenia and
    neurodevelopmental-disorder risk gene whose carriers are sometimes given a
    mood-disorder diagnosis?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#SETD1A
  rationale: >-
    SETD1A is one of the most robustly established schizophrenia risk genes
    (genome-wide significant for rare loss-of-function variants in Singh et al.
    2016, and one of ten exome-wide-significant genes in SCHEMA). Its
    relationship to bipolar disorder is not established. The only direct
    evidence is a founder-population missense allele associated with a 1.8-fold
    relative risk at P = 0.027 - nominal, uncorrected, single-population, and
    reported in a non-peer-reviewed preprint. Three things make this hard to
    resolve rather than merely under-powered. (1) The allele is 55-fold enriched
    in the Old Order Amish and rare elsewhere (0.09% in gnomAD), so direct
    replication in an unrelated cohort is not feasible for this variant; any
    replication has to be at gene level, on a different allelic series. (2) The
    schizophrenia association is driven by loss-of-function alleles, whereas
    P596L behaves as a hypomorph in patient-derived iPSCs, so a gene-level
    bipolar test is not testing the same perturbation. (3) Bipolar and
    schizophrenia diagnoses are not cleanly separable in carriers of large-effect
    chromatin-regulator variants, so a positive gene-level result would still
    need to distinguish a bipolar-specific effect from diagnostic assignment
    within a shared psychosis-spectrum liability. Until then the entry records
    the allele as a lead, not as a susceptibility locus comparable to CACNA1C or
    ANK3.
  proposed_experiments:
  - experiment_id: exp_bipolar_setd1a_gene_burden
    name: Gene-level SETD1A rare-variant burden test in large bipolar cohorts
    description: >-
      Test rare damaging SETD1A variation for association with bipolar disorder
      in the largest available bipolar exome or genome collections, stratified by
      variant class (protein-truncating versus damaging missense), and
      conditioning on schizoaffective and psychotic-feature status to separate a
      bipolar-specific signal from shared psychosis-spectrum liability.
    experiment_type:
      preferred_term: rare-variant burden association study
    decision_criterion: >-
      A bipolar-specific role would be supported by exome-wide-significant
      SETD1A burden in bipolar cases that survives conditioning on psychotic
      features; a signal that disappears under that conditioning, or that is
      carried entirely by protein-truncating alleles with no missense
      contribution, would instead argue that the P596L finding reflects the
      known schizophrenia and neurodevelopmental association rather than a
      distinct bipolar mechanism.
  evidence:
  - reference: PPR:PPR1277941
    reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was associated with a 1.8-fold relative risk for BD in our sample (P = 0.027; Fig. 1A)."
    explanation: >-
      The nominal, single-population association that motivates the gap.
  - reference: PPR:PPR1277941
    reference_title: "Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with bipolar disorder risk and cognitive deficits in specific sub-domains."
    explanation: >-
      The authors' own summary of what the variant is and is not shown to do -
      a risk association plus selective cognitive deficits, with no claim of an
      established bipolar-disorder locus.
- discussion_id: gap_bip_ocd_3p21_1_effector_gene_and_h3k27ac
  prompt: >-
    Which gene at the 3p21.1 locus carries the risk signal shared between
    bipolar disorder and obsessive-compulsive disorder, and is prefrontal-cortex
    H3K27ac histone acetylation the regulatory mechanism through which it acts -
    or is the ITIH3/ITIH4 prioritization an artifact of the long-range linkage
    disequilibrium that also spans GLT8D1, SFMBT1, NEK4 and NISCH?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#ITIH3
  rationale: >-
    3p21.1 is genome-wide significant in the largest GWAS of both disorders, and
    a 2026 cross-trait analysis (conjFDR, SMR, multi-omic colocalization)
    prioritizes ITIH3/ITIH4 as the shared pleiotropic signal, with SNPs
    colocalizing with H3K27ac haQTLs in prefrontal cortex. That result is
    preprint-level, statistical, and directly contradicted in its gene
    assignment by the only functional dissection of the region published to
    date: CRISPR-Cas9 editing of rs2535629, which lies inside an ITIH3 intron,
    changed expression of the distal genes GLT8D1, SFMBT1 and NEK4 rather than
    of ITIH3, and the authors attributed schizophrenia risk to SFMBT1. So an
    intronic ITIH3 variant is a bona fide chromatin-regulatory variant at this
    locus while ITIH3 is not its target - which is precisely the confound a
    colocalization-only analysis cannot resolve. Resolving this matters because
    the two candidate effectors imply different biology: ITIH3/ITIH4 are
    hyaluronan-binding extracellular-matrix cross-linkers (the theme already
    represented by the bipolar NCAN locus), whereas SFMBT1 is a polycomb-family
    chromatin regulator of dendritic spine density. The clinical stake is real
    rather than hypothetical: OCD comorbidity in bipolar disorder is associated
    with a measurably worse course, so a shared causal mechanism would be a
    tractable target.
  evidence:
  - reference: PPR:PPR1294131
    reference_title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "where multiple SNPs (e.g., rs3774364) colocalized with H3K27ac histone acetylation QTLs in the prefrontal cortex (PP_H4 > 0.5)"
    explanation: >-
      States the preprint's specific mechanistic proposal - prefrontal-cortex
      H3K27ac histone-acetylation QTL colocalization at the prioritized locus -
      which is one side of this gap.
  - reference: PMID:34978167
    reference_title: "Regulatory Variant rs2535629 in ITIH3 Intron Confers Schizophrenia Risk By Regulating CTCF Binding and SFMBT1 Expression."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Interestingly, differential expression analysis of GLT8D1, SFMBT1, and NEK4 suggested that rs2535629 may confer schizophrenia risk by regulating SFMBT1 expression."
    explanation: >-
      The one functional dissection of a 3p21.1 psychiatric risk variant assigns
      the effect of an ITIH3-intronic SNP to distal genes, concluding SFMBT1 is
      the mediator. PARTIAL because the disorder studied was schizophrenia, not
      bipolar disorder or OCD; it constrains the gene assignment at this locus
      rather than settling it for these two disorders.
  - reference: PMID:40855518
    reference_title: "Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BD-OCD presents a more severe and complex clinical profile, requiring specialized assessment and integrated treatment approaches."
    explanation: >-
      Peer-reviewed meta-analysis of 22 studies establishing that the
      bipolar-OCD comorbidity carries a distinct and more severe clinical
      profile, which is why a shared causal locus is worth resolving.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE328018
  title: Choroid plexus inflammation in bipolar disorder
  description: Postmortem human choroid plexus tissue from individuals with bipolar disorder and matched controls was analyzed using cytokine protein arrays and bulk RNA sequencing to characterize immune and barrier-related alterations. The study identifies increased pro-inflammatory signaling and reduced trophic/supportive pathways, implicating the choroid plexus as a neuroimmune interface in bipolar disorder.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 23
  publication: PMID:41980683
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE306819
  title: Single-nucleus RNA sequencing in the post-mortem thamaus and cortex in bipolar disorder
  description: We performed high-throughput single-nucleus RNA sequencing (snRNA-seq) using the 10x Genomics Chromium platform on archived postmortem thalamus and frontal cortex (BA10) tissues from patients with bipolar disorder and control subjects to identify cell type–specific differentially expressed genes and compositional changes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 82
  publication: PMID:41501055
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE241671
  title: Differential effects of lithium on metabolic dysfunction in astrocytes derived from bipolar disorder patients
  description: Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by biphasic mood episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes in BD patients remain largely unknown and have not been extensively studied. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients and their responses to lithium treatment. The gene expression profiles of iAstrocytes from BD patients (BD iAstrocytes) indicate dysregulation of metabolic processes in BD iAstrocytes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 30
  publication: PMID:40847005
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00000000001
  title: WTCCC case-control study for Bipolar Disorder
  description: WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00000000002
  title: WTCCC case-control study for Bipolar Disorder - Combined Controls
  description: WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001003085
  title: Exome sequencing in bipolar disorder families
  description: Bipolar disorder (BD) is a major psychiatric disorder affecting around 1% of the global population. BD is characterized by recurrent manic and depressive episodes, and has an estimated heritability of around 70% Research has identified the first BD susceptibility genes. However, the underlying pathways and regulatory networks remain largely unknown. Since research has shown that the cumulative impact of common alleles with small effect appears to explain only around 25-38% of the phenotypic variance for BD, rare variants of high penetrance may also contribute to BD risk.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST001946
  title: Bipolar disorder metabolomics analysis using FiehnLib and GMD for curation
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
- accession: massive:MSV000086425
  title: Dysregulation of the complement and coagulation cascade in treated schizophrenia and bipolar disorder patients
  description: A better understanding of the proteomic profile after bipolar disorder (BD) and schizophrenia (SCZ) treatment, through monitoring its progression, may assist the development of novel therapeutic strategies with the ability to reduce or control possible side effects. In this study, proteomics analysis employing liquid chromatography coupled to mass spectrometry (LC-MS) and bioinformatic tools were applied to identify differentially expressed proteins in serum of treated BD and SCZ patients. In total, 10 BD patients, 10 SCZ patients, and 14 healthy participants were included.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
- accession: dbgap:phs000866
  title: Family Genomics of Bipolar Disorder
  description:  This study examined the segregation of variants with phenotype in pedigrees harboring bipolar disorder.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
references:
- reference: PPR:PPR1294131
  title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
- reference: PMID:34978167
  title: "Regulatory Variant rs2535629 in ITIH3 Intron Confers Schizophrenia Risk By Regulating CTCF Binding and SFMBT1 Expression."
- reference: PMID:40855518
  title: "Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis."
- reference: DOI:10.1503/jpn.230112
  title: Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
  findings: []
- reference: DOI:10.3389/fnins.2023.1228455
  title: Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder
  findings: []
- reference: DOI:10.3389/fpsyt.2024.1414776
  title: 'The genetic association between bipolar disorder and dementia: a qualitative review'
  findings: []
- reference: DOI:10.3390/biology13100787
  title: 'Codes between Poles: Linking Transcriptomic Insights into the Neurobiology of Bipolar Disorder'
  findings: []
- reference: DOI:10.3390/brainsci14121199
  title: 'Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review'
  findings: []

📚

References & Deep Research

References

8

PPR:PPR1294131

Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder